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Inhaled corticosteroids treatments have been previously shown to 
decrease bone mineral density{BMD) while fluoride has been repeatedly 
shown to increase BMD. The effects of obstructive airway disease(OAD) and 
inhaled corticosteroids treatment on BMD and body composition in Hong 
Kong Ghinese patients were studied in phase I study. For phase II of the 
study, the effect of fluoride on BMD and body composition in Hong Kong 
Ghinese patients with OAD had been studied. 
In phase 丨 of this study, we had investigated the BMDs and body 
composition in 144 OAD patients, among them 106 (Group I consisted of 37 
premenopausal female; group 11, consisted of 36 postmenopausal female, 
and group IV comprised 33 male) were on a dosage of 800 i^g inhaled 
corticosteroid or more a day and 38 did not take any corticosteroid(Group III 
consisted of 14 postmenopausal female and group V consisted of 24 male). 
The mean duration of taking inhaled corticosteroids was 45 土 17 weeks 
(ranging from 16 to 76 weeks) for group I’ 42 土 13 weeks (ranging from 14 
to 64 weeks) for Group 11, and 40 土 11 weeks (ranging from 20 to 62 weeks) 
for group IV. For the control group, each OAD patient was matched with two 
normal subjects adjusted for age(within 土 2 year), BMI(within 土 10 o/o) and 
sex. The BMDs of the total body, lumbar spine(L1-L4), femur neck, 
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intertrochanteric region, and Ward's triangle, and the body composition of 
each participant was measured by dual energy X-ray absorptiometry 
(DEXA). 
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The total body BMDs of the pre-menopausal women(group I) and the 
OAD men not on inhaled steroids{group V) were found significantly lower 
than those of the controls(p<0.05) and. The lumbar spine BMDs were found 
significantly lower(p<0.01)than the controls both for OAD men(group V) and 
post-menopausal OAD women(group 11) on inhaled steroid. Comparing with 
the control groups，the BMDs of the femoral neck, intertrochanteric region 
and Ward's triangle were significantly lower among OAD men with inhaled 
steroids(p<0.05, p<0.01, and p<0.05, respectively) or without inhaled 
steroids(p<0.001, p<0.001, and p<0.01, respectively). 
In addition, there was significantly difference in the lumbar spine(L1-
L4) BMD between the OAD patients{men and women) with and without 
inhaled steroids therapy. 
Inhaled steroids at the dosage of 1522 土 508 pg per day for 42 土 13 
weeks did not decrease the total body BMD. However, lower BMD was noted 
at the lumbar spine(L1-L4), among all the subjects using inhaled 
corticosteroids, and the elderly OAD male patient (group V) who had never 
taken any inhaled corticosteroid treatment, compared with the controls. With 
OAD women, their hip BMDs were less affected by inhaled corticosteroids 
than those men at similar age. 
Pre-menopausal women treated with inhaled steroids have a higher 
fat mass, compared with their controls. OAD or inhaled steroid inserted 
insignificant effect on body composition. 
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In phase II of this study, the effects of fluoride and / or calcium on 
BMD were studied among 82 〇AD patients currently on inhaled 
corticosteroid were studied. They were grouped by sex, age(within 土 2), and 
BMI(within 土 1C)o/o) and randomly allocated for Tridin (fluoride and calcium) or 
calcium therapy. Their response to Tridin and or calcium treatments were 
documented by sequential measurements of their BMDs at lumbar spine (L1-
L4) and proximal hip. 
Subjects developed significant side-effects with Tridin and calcium 
treatments 4 and 2 patients could not tolerance Tridin and calcium therapy, 
respectively. Other patients withdrawn f「om the study for the following 
reasons, 3 died of unrelated conditions, 1 was lost to follow up, 4 were 
uncooperative and 6 quitted for personal reasons(Table 7.5.a.). The 
remaining patients were followed for 9 months. Results were analysed 
accordingly, group 丨 consisted of all the 30 pairs' patients, group II consisted 
of 12 pairs of male, group III consisted of 18 pairs of female, group IV 
consisted of 9 pairs premenopausal female and group V consisted of 9 
pairs of postmenopausal female. 
There was no significant difference in daily calcium intake between 
the Tridin group(median = 371 mg) and calcium group(median 二 434 mg). 
The compliance was 59 ±4(rangingfrom16to100o/o)forthose with Tridin 
and 67 土 24(ranging from 16 to 97%) for those with calcium. Tridin group 
showed a lower level of hip and lumbar spine(L1-L4) BMDs than those of 
calcium group. However, the differences were not statistically significant. On 
the other hand, male subjects taken Tridin(Table 7.4.b.) showed 
vi 
significantly lower Ward's triangle BMD(p<0.05, figure 7.4 b) than those 
taken calcium only. 
Patients responded more favourably to calcium than to Tridin 
therapy(table 7.7). However, this might be due to the small sample size. 
The BMDs of the group given Tridin were lower than those of the 
group given calcium. Tridin or calcium treatment did not increase BMDs at 
the lumbar spine(L_1-L4) or the hip. Site specific bone lose due to Tridin 
treatment was observed in male and premenopausal female OAD patients, 
whose bone density lost more rapidly at hip than lumbar spine. On the 
contrary, no site specific lose was observed among the calcium treatment 
group. Further studies are needed to determine the effective dose of Tridin 
or calcium for the OAD patients. 
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Chapter 1 Obstructive airway disease: Public 
health and clinical aspects 
1.1. Background 
〇「al steroid therapy is well known for its adverse side effect on bone 
density. The trend is be replace oral steroids by inhaled corticosteroids 
therapy for the treatment of obstructive airway diseases(OAD) such as 
asthma and chronic obstructive airway disease(COAD)(Report, I. C., 
1992).This has led to investigations into whether inhaled steroid therapy 
leads to bone loss. 
The measurement of bone mineral density with dual energy X-ray is 
now a valuable tool for studies of body composition and skeletal status for 
the health and the disease. Rapid, accurate and precise measurement can 
be repeated with much lower doses of radiation. It also allowed total body as 
well as regional skeletal bone mineral density to be measured. 
The relationship between inhaled steroid therapy and osteoporosis 
will be studied in Ghinese asthmatic patients. The mean daily calcium intake 
of Hong Kong Chinese is less than 500 mg per day(Lau, E. , Woo, J. et al, 
1992), and inhaled steroids may have a larger impact on bone mineral 
density(BMD) than in Caucasians. In phase 丨 of this study, the effects of 
inhaled steroid on BMD and body composition will be investigated. 
Premenopausal and postmenopausal asthmatic Chinese women and 
asthmatic Ghinese men age 45 or above will be studied. The effect of 
丨 1 
obstructive airways disease per se 0门 body composition and BMD will also 
be investigated. 
In phase II of this study, the effect of fluoride (Pouilles, J. M., 
Tremollieres, F. et al, 1991; R iggs ,已.L , W M , 〇 . F . et al, 1994) in 
preventing bone loss in men and women with inhaled steroid therapy for 
asthma and chronic obstructive airway disease (COAD) will be investigated. 
1.2. Magnitude of the problem 
1.2.1. Asthma 
In England, diagnosis of asthma is coded according to the rules of the 
International Classification of Disease (ICD). These rules are revised 
periodically, and changes in coding rules have produced small artificial 
increases in death-rates in 1979 and in 1984. Currently, 10% of children and 
K 
7.5% of adult( totally 2.5 million people) in England and Wales are having 
asthma. 
Prevalence rates vary markedly between different countries, 
accounted for in pa「t by differing diagnostic approaches and a more 
important source of error is that due to diagnostic uncertainty. Under the age 
of five, deaths attributed to asthma are exceeded by deaths ascribed to other 
respiratory disease (pneumonia, bronchitis and bronchitis, and upper 
respiratory tract infection). Asthma death-rates in older children and young 
adults are probably more「eliable in that other respiratory disease are often 
less fatal. The actual numbers of childhood death in England are few; less 
than 10 deaths per yea「among 5 and 14 year age group. 
2 
.( 
In the Western countries, the prevalence varies between 12o/o and 
23%, whereas in Asia the prevalence is among 2% and 90/o(Leung, R., 
Bishop, J. et al, 1994). There is also accumulating evidence that the 
prevalence of asthma is increasing in both the Western and i^sian 
countries(Lau, 丫. L., Karlberg, J. et al, 1995). 
The prevalence of asthma in children aged 3 to 10 in Hong Kong is 
6%(Lau, E., Egger, P. et al, 1995), similar to that in Singapore(4.8%) and in 
Taiwan(5.8%) but is lower than that in Japan(11%) and in 
Malaysia(13.8%)(Leung, R. and Ho, P., 1994). Recently, study has shown 
the age-specific prevalences of asthma among Hong Kong young children 
were 10% at age 7, 8% at age 12, and 7% at age 15 (Leung, R.,Bishop, J. 
and Robertson. C. F., 1994). 
The number of death due to asthma in Hong Kong was 3.2 per million 
in 1976 and rose to 6.7 per million in 1985(So, S. Y., Ng. M. M. et al. 1990). 
Similar trend has been observed elsewhere. 
1.2.2. Chronic obstructive pulmonary disease 
Chronic obstruction airway disease (COAD), is a destructive and 
obstructive disease of the airways associated with disruption of the ciliated 
I mucosa and airway obstruction. Damage to alveolar walls and permanent 
i 
loss of the pulmonary capillary bed occur. COAD occurs commonly among 
the elderly in Hong Kong, especially among the smokers. 
Symptoms of OAD patients vary from occasional wheeze to serve 
respiratory difficulty leading to hospitalisation. OAD patients account for 8% 
丨 3 
of total hospital admission in a Hong Kong hospital(Wong, 丁. W. and Lam, 
K. W., 1994). Most of the patients required life-long treatment. 
Between 1989 to 1994, OAD patients account for 3.3 to 3.7% of the 
total hospital admission(table 1.1), and OAD mortality account for 6.9 to 
8.2% of the total deaths in Hong Kong. The OAD mortality ratio between 
male and female was about two. OAD patients in Hong Kong had a mortality 
rate of twice as much as those with other diseases. 
Between 1984 to 1994, OAD was one of the ten major causes of 
death in Hong Kong(Department report, 1984-1985; 1993-1994). 
1.2.3. Prevalence of osteoporosis in Hong Kong 
The incidence rate of hip fracture in hlong Kong has increased 3-fold 
since 1966 to reach 9 per 1000 in men and 13 per 1000 丨门 women aged 80 
and over in 1989(Lau, E. M. and Cooper, C., 1993). Similar observations 
have been made in Singapore(Lee, S. and Lee, K., 1988) and Japan(Orimo, 
H., 1990). Another Hong Kong study has indicated that about 200,000 
patients among a population of 6 million were affected by osteoporosis(Pun, 
K. K., Wong, F. H. etal, 1991). 
Osteoporosis is a major public health problem in most developed 
countries. In the United States, it has been estimated that 20-25 million 
people are osteoporotic which manifested as 240,000 hip fractures, over 




1.2.4. History of asthma care 
Asthma is recognised nearly 4000 years ago in Ghina and was 
treated with leaves of the plant Ep/7edra(Teeling-Smith, G.，1990). it is not 
until 1920s that ephedrine is first used in Western medicine. The word 
asthma derives from a Greek word meaning difficulty in breathing. 
Hippocrates has described asthma and recognised that it could be fatal. By 
the 16th century, it is noted that asthmatics were affected by feather pillows, 
dust and changes in weather(Teeling-Smith, G., 1990). 
1.2.5. Treatment of OAD 
Theophyllines, bronchodilaters, and corticosteroids have been used 
to treat OAD. Theophyllines are bronchodilators with a central stimulant 
action. Side-effects range from nausea, vomiting, and sudden deaths have 
been reported. Other bronchodilaters included short acting beta-2 agonists 
which stimulate the beta-2 adrenergic receptors in the bronchial smooth 
muscle, causing relaxation. They also enhance mucociliary clearance 3nd 
decrease vascular permeability. Inhaled long acting beta-2 agonists are 
usually given for their protective effect against bronchospasm. They are ’ 
relatively free of side-effects and are of low toxicity, as compared with long_ 
acting oral beta-agonists and theophyllines. However, tremor, palpitation, 
J and headache may occur in some patients. Anticholinergics block post-
il 
ganglionic vagal pathways, so reducing vagally-induced bronchconstriction. 
？ ] i'\ 
1 Side-effects include blurred vision, urinary problems, and dry month. 
M '] 
丨 Prevention and anti-inflammation are the two major roles of 
ii 
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and, local hormonal and chemical pathways, and reduce mucus viscosity 
and increase beta-receptor responsiveness. 
Inhaled corticosteroids in low doses are used for the management of 
mild to moderate asthma, and higher doses (more than 800 ^ig a day) are 
used in patients with more serve asthma. They control the underlying 
inflammation and thereby reduce the severity and frequency of acute 
attacks. The dose may be temporarily increased to give added protection at 
times of increased risk, such as during an upper respiratory tract infection. It 
is believed that inhaled corticosteroids may prevent the long-term damage to 
the lungs that might have otherwise occur in OAD patients. For most cases, 
inhaled steroid is the drug of choice for good control(Barnes, N. C., 1993; 
Lai, C. K., Chan, C. H. etal, 1995). 
1.3. Side effects of Glucocorticoid in OAD patients 
Systemic steroids are well known for their adverse effects on bone. 
They can lead to progressive loss of trabecular bone, hence increasing the 
risk of fractures The effects are likely to be dose and duration related. Other 
side-effects include adrenal suppression, raised blood glucose, psychiatric 
problems, weight gain, thin skin, redistribution of fat, oral thrush, and 
hirsutism in woman. 
It has been previously reported that Glucocorticoid treatment are 
associated with increased bone resorption. BMD may be reduced by 10-20 
% at the hip and the spine(Brandli, D. W.，Golde, G. et al, 1991). Decrease 
6 
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in calcium absorption from the intestinal tract, inhibition of osteoblast and 
increase in urinary calcium loss may occur. However, administration of 
glucocorticoids on alternative days does not reduce the risk of bone 
loss(Medici, T. C. Ruegsegger, P., 1990). 
One study has shown that glucocorticoids suppressed growth in 
children as a result of reducing circulating oestrogen or testosterone, 
through actions on the pituitary, gonad or adrenal glands(MacKenzie, C. A., 
Weinberg, E. G. et al, 1993).丨门 other studies no evidence of adrenal 
suppression occurred in children, if four or fewer courses a year were given, 
with each course less than three weeks(Balfour-Lynn, L., 1986). 
1.4. Side effects of inhaled corticosteroids in OAD patients 
In recent years inhaled corticosteroids have been prescribed in higher 
dose than previously. This has caused increasing concern about the 
systemic side-effects similar to those associated with the oral use, 
particularly when the inhaled doses have exceeded 1000 \jg a day. 
The effects of systemic corticosteroids administration on children's 
growth have been extensively studied (Balfour-Lynn, L., 1986; Shohat, M., 
Shohat, T. et al, 1987). There was no suppression of normal growth in 
children who received less than 800 mg a day of beclomethasone or 
budesonide, for up to eight years. In pre-school children, no growth 
suppression was found at doses less than 400 \jg a day. On the other hand 
！ 
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similar dose of inhaled beclomethasone dipropionate (Wolthers, 0. and 
Pedersen, S., 1991) has been shown to be effectively in leg growth 
suppression in another study. Recently, several studies reported that bone 
density was not affected in asthmatic children and women taking inhaled 
beclomethasone for 6 to 12 months(Baraldi| E., BolIini, M. C. et al, 1994; 
Herrala, J., Puolijoki, H. et al, 1994). However, one Hong Kong study 
reported a decrease in BMDs of lumbar spine, neck of femur, and trochanter 
in female asthmatic patients, after taking budesonide or beclomethasone 
dipropionate for an average of 40 months(3-180 months). In contrast, there 
was no statistically significantly differences in BMDs between those male 
patients and their matched control subjects(lp, M., Lam, K. et al, 1994). 
At higher dose, inhaled steroids inhibits adrenal production of 
androstenedione secretion, which is of particular concern among 
postmenopausal woman, since the conversion of androstenedione to 
oestrogen in adipose tissue is their principle source of oestrogen(Crilly, R. 
G., Cawood, M. et al, 1988). 
1.5. Trend of asthma therapy in Hong Kong 
Inhaled steroids become the primarily choice for asthma therapy in 
Hong Kong. During 1984-1986. oral anti-asthmatic agents (beta-agonists) 
were used more commonly than inhaled drugs, and inhaled therapy mainly 
consisted of non-selective beta-agonists. Steroids were rarely used(Kumana, 
C. R., So, S. 丫. et al, 1989). In 1987, aminophylline was mostly used to treat 
丨 8 
chronic adult asthma, and inhaled beta-agonist was used in the maintenance 
therapy for adult and children asthmatics. Inhaled steroid was only the 
second line drug. In 1992, inhaled steroids become the drug of choice in 



























































































































































































































































































































































































































































































































































































Chapter 2: Osteoporosis: Public health and 
clinical aspects 
2.1. Bone Biology 
Bones are composited of calcium and phosphorous crystals, held 
together by protein fibres. Calcium produces the strength and rigidity in 
bones, and proteins allow flexibility. Other minerals that help holding bone 
cells together are fluoride, sodium, potassium and magnesium. 
Bone resorption by the osteoclast plays an essential role in the 
homeostasis of both the skeleton and serum calcium. This cellular process is 
essential in the growth and remodelling of bones, and it is tightly coupled to 
the process of bone formation by the osteoblast. Goupling of these two cell 
types are necessary for the maintenance of skeletal health. The disruption of 
the coupling between bone resorption and formation may lead to conditions 
such as osteopetrosis, osteosclerosis or osteoporosis. 
2.2. Skeletal Organisation 
The skeleton consists of mostly enchondral bones, which are the 
results of secondary transformation of cartilage, and membranous bone such 
as the flat bones of the skull, which are originated from the mesenchyme. 
The enchondral bone has two components, peripheral (the compact bone or 
the cortical bone) and central (bone marrow). The cortical bone accounts for 
80% of the total skeletal mass and is composed of plates bone called 
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lamellae. Lamellae are organised about the central Haversian nutrient 
canals. The bone marrow consists of a honeycomb of vertical and horizontal 
bars called the trabecular or woven bone, and it is filled with red marrow and 
fat.丨门 adult human, trabecular bone is the sole repository of red marrow, 
localised in most parts of the ve「teb「al bodies, the long bones and pelvis. 
The metaphyseal ends of adult long bones also contain trabecular bones but 
not bone marrow. 
2.3. Bone remodelling 
Bone remodelling is a coupled process, the resorption phase of bone 
remodelling in cortical bone takes about 15 days. It begins with the formation 
of bone multicellular unit(BMU) that consists of tunnel (cutting cone) drilled 
out by advancing osteoclasts. Bone formation in the BMU begins with the 
differentiation of preosteoblasts into osteoblasts. Afterward, they form the 
matrix, which becomes mineralised and fills out the tunnel except for the 
central Haversian system constitutes a new cortical bone structure unit 
(BSU). 
Bone remodelling in cancellous bone is identical, except that the 
resorption period lasts about 50 days and can be subdivided into three 
stages: the osteoclastic stage, the mononuclear stage and the 
preosteoblastic stage. Matrix formation lasts for 15 days followed by 
mineralization for another 130 day. Thus, it takes around 150 days to form a 
new cancellous BSU. 
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2.4. Effect of corticosteroids on bone remodelling 
The major effect of corticosteroids appears to be the depression of 
osteoblastic function. This can be demonstrated histomorphometrically as a 
reduction in mean wall thickness, lamella thickness, osteoid surface and 
osteoid seam width(Aaron,丄 E., Francis, R. M. et al, 1989).丨门 tissue culture 
experiments, both osteoblastic replication and differentiation are inhibited by 
corticosteroids(Lukert, B. P. and Raisz, L G., 1990). The osteoblasts also 
had a shortened life span(Dempster, D. W.. Arlot, M. A. et al, 1983). In 
contrast to osteoblastic activity, osteoclasts were not abundant at resorption 
surfaces. Thus, the net loss in bone mass during corticosteroids treatment 
could be the result of reduced bone formation rather than increased 
osteoclastic activity(Lundy, M. W., Stauffer, M. et al, 1995). 
Elevated parathyroid hormone (PTH) level during corticosteroids 
therapy causes reduction of calcium absorption from bowel and its the renal 
reabsorption. It also increases the formation of new remodelling units, and 
the net decrease in bone mass would be amplified. 
2.5. Corticosteroids induces osteoporosis 
The microanatomical appearance of corticosteroid-induced 
osteoporosis differs from that of idiopathic osteoporosis(Aaron, J. E., 
Francis, R. M., et al 1989). The numbers of trabecular bone and their 
surface area are relatively preserved in corticosteroid induced osteoporosis, 
but individual lamella plates are very thin. For idiopathic osteoporosis, the 
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major driving force to bone loss is osteoclastic resorption. The trabecular 
width is relatively preserved, but the lamellae were perforated by resorption, 
with a loss of trabecular surface and continuity. 
2.6. Factors affecting BMD 
2.6.1. Peak bone mass 
Development of osteoporosis appears to be related to the peak bone 
mass attained at young adulthood and to the rate of bone lose thereafter. 
Peak bone mass is attained between the ages of 20-35(Bonjour, J. P., 
Theintz, G. et a!, 1991; Sugimoto, T., Tsutsumi, M. et al, 1992). This age 
varies with sex, race, calcium intake, geography location and exercise.(Ho, 
S. C., and Hsu, S. 丫. et al. 1993; Ho, S. C., and Leung, P. C. et al 1994). 
2.6.2. Ethnic factors 
Several studies suggested BMD varies in subjects of different ethnic 
origins. Chinese, Korean and Japanese of the same age have similar BMD, 
and the optimal peak bone mass achieves at the age between 30-
39(Norimatsu, H., Mori, S. et al, 1989; Bonjour, J. P.,Theintz, et al, 1991; 
Sugimoto, T.,Tsutsumi, M., et al, 1992). In contrast, Caucasians reach their 
peak bone mass at a「omd 30. The mean BMD of Korean woman was 11.1 
% lower than their Caucasian counterpart. Other study revealed that 
American Blacks have higher BMD than American Caucasians(C6te, K. D. 
and Adams, W. C., 1993; Bell, N. H., Gordon, L. et al, 1995). 
丨 1 4 
One study on Japan-born and US-born Japanese American women 
reported that the BMD among US-born Japanese American was higher than 
those born in Japan(Kin, K., Lee, J. H. et al, 1993). This suggests a 
modification effect of the environment on genetic factors. 
2.6.3. Aging 
Bone loses with aging(Lips, P., Courpron, P. et al, 1978; Kragstrup, 
J., Melsen, F. et al, 1983). Like most biological process, bone remodelling is 
not entirely efficient, the amount of new bone formed is not always equal to 
the amount previously removed, so that a small bone deficit persists after 
each cycle. This inefficiency is called remodelling imbalance and the 
accumulation of this deficit over the years may lead to osteoporosis. 
The pattern of age 「elated bone loss varies with different types of 
bone. In cortical bone, there is a prolonged slow phase of bone loss that 
begins at about age 40 in both males and females. The initial rate of loss of 
0.3 to 0.5 % per year increases with age, but declines or stops very late in 
life span(Mazess, R. B., 1982). In women, there is a more rapid phase of 
bone loss that begins at menopause and may reach 2-3 % a year for 8-10 
years after their menopause. Both men and women begin to lose trabecular 
bone at the age of 30-35(Mazess, R. B., 1982). 
2.6.4. Calcium intake 
Greater calcium intake early in life may have a beneficial effect upon 
adult bone mass, whereas increase dietary intake at later life seems to have 
15 
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lesser effect 0门 bone mass. The daily calcium intake in Hong Kong Ghinese 
is about 350-450 mg per day(Lau, E. M.,Woo, J., et al, 1992), but in Finland 
it is about 1g in adult(Kroger, H. and Laitinen, K., 1992); 1.6g in boys and 1 
g in girls(Andersen, L. F., Nes, M. et al, 1995; Andersen, L. F., Nes, M. et al, 
1995). 
2.6.5. Oestrogen 
Oestrogen deficiency is the major cause of decreased skeletal mass 
in woman. Postmenopausal bone loss is associated with falling oestrogen 
level, and some success in skeletal preservation has been achieved by 
using hormone replacement therapy after menopause or ovariectomy. 
Skeletal growth and maturation in girl at puberty is associated with a rise in 
oestrogen level. Bone mineral density is lower in a hypogonadal woman 
regardless of its cause(Richelson, L., Wahner, H. et al, 1984). Moreover, a 
postmenopausal woman will lose 13% of her total bone mass within 15 years 
after her menopause. 
It has been demonstrated that oestrogen inhibits the lnterleukin-6(IL-
6) production by cultured bone marrow stromal and osteoblastic cell lines, as 
well as primary bone cell cultures from rats and human(Girasole, G., Jilka. R. 
et aI, 1992). (With oestrogen loss, this inhibitory effect is lessened, resulting 
in an up-regulation of IL-6 which stimulates osteoclasts production and then 
increases bone resorption). Injection of anti-IL-6 antibody has been shown to 
inhibit osteoclast activity in human(Klein, B., Wijdenes, J. et al, 1991). 
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2.6.6. Alcohol consumption 
Alcohol consumption has been implicated as an important aetiological 
factor in the development of osteoporosis in men(Cohn, K., Sartoris, D. et al, 
1992). The incidences of rib and vertebral fractures were higher in 
alcoholics(Schapira, D., 1990). In one study (Odiva, C. V., Safi, I. et al, 
1995), the effect of prolonged alcohol consumption on bone mineral density 
in both black(n=21) and white(n=19) male subjects without significant 
hepatic disease were evaluated. No significantly differences were found in 
BMD values for lumbar spine, total hip, and femoral neck were found 
between the alcoholics and their control subjects. However,丨门 white 
subjects, age(p : 0.013), and duration of alcohol intake (p = 0.002) had 
significant independent effects on the BMD of spine. However, the duration 
of alcohol intake (p = 0.029) was the only factor with independent effect on 
the bone density of hip. In black subjects, age was the only independent 
factor affecting the bone densities of spine and hip(p = 0.009 and 0.014, 
respectively). 
2.6.7. Cigarette smoking 
Smoking has been shown to be associated with low bone mass in 
young pre-menopausal female(Mazess, R. B. and Barden, H. S.. 1991), and 
elderly men{Pocock, N. A., Eisman, J. A. et al. 1989). 
2.7. Physical activity and BMD 
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BMDs are higher in physically active individuals. One recent cross-
sectional study on pre-menopausal women has shown that the BMDs at the 
lumbar spine and hip of the walkers and aerobic dancers were higher than 
those of the non-exercisers(Alekel, L., Clasey, J. L. et al, 1995). These 
findings suggested walking and aerobic dancing exercise may provide the 
physically active pre-menopausal women with higher lumbar and femoral 
BMDs than that of the sedentary females. 
The site specific changes in BMD of hip are observed(Lee, E. J., 
Long, K. A. et al, 1995). Basketball player has shown the highest hip BMD. 
This is followed by swimmer, moderately active control subjects and 
sedentary control subjects. 
2.8. Body composition in Chinese subjects 
Body composition analysis, particularly the estimation of fat-free 
mass and total body fat, forms part of the nutritional assessment process. It 
offers more information than body mass index(BMI), since changes in body 
weight may be the result of changes in either component. Previous report 
has revealed that the BMD of female is associated with body fat 
mass(Beshyah, S. A., Freemantle, C. et al, 1995). Thus, it is important to 
study the body composition of human beings. Body fat mass is related to 
blood pressure and other cardiovascular disease risk factors, glucose 
intolerance, insulin resistance, BMD, and osteoporosis. 
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ln the past decade, non-invasive dual energy X-ray 
absorptiometry(DEXA) had been developed for the estimation of body 
composition(Fuller, N. J., Jebb, S. A. et al, 1992; Johansson, A. G., 
Forslund, A. et al, 1993). It was found to be a more precise method of 
measuring body composition compared with skin-fold thickness 
measurement. 
Previous studies among Hong Kong Chinese have shown that both 
lean body mass and body fat in addition to body weight are significant 
associated with BMD in woman aged 31 to 40(Pun, K. K., Wong, F. H., et al 
1991). Moreover a comparative study on BMD between 575 healthy 
premenopausal and postmenop3usal Ghinese women living in Hong Kong 
and Taiwan have concluded body weight is a significant predictor of BMDs 
for hip and spine(Lau, E. M. C., Tsai, K. S. et al, 1995). 
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Chapter 3 Phase I: Body composition and bone 
mineral density in obstructive airway 
disease patient and normal control 
subjects: Objectives, Subjects and 
methods 
3.1. Objectives 
The objectives of this phase of the study were to compare the body 
composition and the bone mineral density (BMD) of obstructive airway 
disease (OAD) patients with normal control subjects, and to study the effects 
of inhaled steroid treatment on the body composition and BMD of the OAD 
patients. The research questions are:-
3.1.1 Are the fat mass, lean mass and percentage fat mass of OAD patients 
lower than that of normal control subjects? 
3.1.2 Are the bone mineral densities at the hip and spine lower in 0>^D 
patients? 
3.1.3 Are the fat mass, lean mass and percentage fat mass of OAD patients 
taking inhaled steroids than that of OAD patients not taking inhaled 
steroids? 
3.1.4 Are the bone mineral densities at the hip and spine lower in OAD 
patients taken inhaled steroids? 
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3.2. Subjects and methods 
3.2.1 OAD patients 
3.2.1.1 Disease definition and selection criteria 
Patients who fulfilled the following criteria were recruited> 
a) Diagnosed to have chronic obstructive airway diseases(COAD) or 
asthma by a qualified physician with membership of Royal College of 
Practitioner, bearing the ICD coding:490-496. 
b) Aged 18 and over. 
c) Have never had a history of metabolic bone disease. 
d) Have been using inhaled steroid regularly for at least 3 months 
e) Have never had a history of chronic systemic steroid use for more 
than 1 month continuously, more than 4 booster courses or having 
systemic steroids in the previous 3 months(lp, M.,Lam, K., et al, 
1994). 
Patients were recruited from the Specialist Respiratory Disease Clinic 
at the Prince of Wales Hospital and the Family Medicine Glinic at the Lek 
Yuen Health Gentre in Shatin. All eligible patients who were registered with 
these clinics were recruited into our study. The study was conducted from 
January 1995 to December 1995. 
3.2.1.2. Normal Control subjects 
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The normal control subjects were volunteers among medical and non-
medical staff and medical students from the Prince of Wales Hospital, 
Shatin. A notice introducing the surrey was sent to the staff members and 
subjects were recruited consecutively. 
Gontrol subjects were matched individually with the patients for sex, 
age(within 土 2 year), and body mass index (within 土 1C)o/o). 
3.3. Power of estimation 
In order to detect a statistical difference of 0.5 with a statistical power 
of 0.75 and type 1 error of 5% between the OAD patients and the control 
groups. The minimum number of patients required for each group is 35. If the 
statistical power is 0.8, the minimum number of patients required for each 
group is 39. 
3.4. Survey methods 
OAD patients were interviewed using a standardised structured, 
questionnaire as they attended the dinics(Appendix 1). They were then 
requested to have their body composition and bone mineral density 
measured. 
Informed consent was obtained from all subjects before the interview 




A standardised structured questionnaire was developed to measure 
the dietary calcium intake, physical activity, medical history, reproductive 
history(for woman), and history of drug treatment and other medical 
conditions of the subjects. The questionnaire was compiled partly from a 
validated questionnaire used previously in studying osteoporosis among 
Hong Kong Chinese(Lau, E. . and Donnan, S., 1988) (Appendix I). 
Dietary calcium intake was assessed by recording the frequencies of 
consumption of 17 Chinese food items during the previous week. These 
items have previously been found to be the main source of calcium intake in 
the Chinese diet. The dietary calcium intake of each food item was 
calculated as the product of the intake frequencies during the past week, the 
weight of an average proton size, and the calcium content of the standard 
portion size which was published in the South East Asia Food composition 
table. Thus, the total calcium intake would be the sum of these products. 
Physical activity was measured by the frequencies of several of load-
bearing activities which had been performed during the past week. 
3.6. Body composition and bone mineral density measurement 
Body composition and bone mineral densities of total body, lumbar 
spine(L1-L4), and left proximal hip were measured with dual x-ray 
densitometry using Hologic QDR-2000 machine(Hologic, MA, USA). This 
machine emits a very low dose of X-ray and the effective dose is less than 
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27mR (0.27mSV), which is approximately half of the dosage emitted for a 
standard chest X-ray. Thus, additional protective procedure was needed to 
shield the patient, operator or room from the exposure. 
3.6.1. Body composition analysis 
Lean mass, fat mass, and body fat percentage were analysed with 
Hologic enhanced array total body software version 5.67A according to the 
protocol supplied by the manufacturer 
3.6.2. Lumbar spine and proximal hip bone mineral density analysis 
BMD at the lumbar spine(L1-L4) was analysed with Hologic array 
spine medium software version V4.74A:1. The BMD at the left proximal hip 
was analysed with Hologic array left hip medium software version V4.59.A:1 
according to the protocol supplied by the manufacturer. BMDs of the Ward's 
Triangle, intertrochanteric region and femoral neck were also measured. 
3.6.3. Routine quality control of measurements 
Standardisation procedure was performed daily by scanning an 
Hologic arthropromatic phantom according to the protocol supplied by the 
manufacturer. The results of these calibrations were entered into the quality 
control database provided. The C.V. was measured, and it was 0.42 % for 
BMD. No drift was seen during the overall period of investigation. 
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3.6.4. Precision on patient repositioning 
To study the CV of repositioning, 20 normal subjects were scanned 
once and then again after repositioning. The CVs obtained were 0.7 % for 
spine, 1.2 % for femoral neck, 1.4 % for intertrochanteric region, and 2.8 % 
for Ward's triangle.〇u「data were similar to those previously reported(Kelly, 
T. L., Slovik, D. M. et al, 1988; Devogeiaer, J. P.，Baudoux, C. et al, 1992; 
Slosman, D.〇.，Rizzoli, R. et al, 1992). 
3.7. Statistical methods 
Differences in life-style factors between OAD patients and control 
subjects were compared by paired t-test or chi-squares test. 
Multiple regression was used to compare the BMDs and body 
composition of the patients with the control subjects, while adjusting for the 
life-style factors. 
The body composition and bone mineral density measurements 
between the OAD patients and the control subjects, and between the OAD 
patients who were with or without steroid therapy were compared by paired t-
test. 
3.8. Bone mineral density of normal control subjects 
The BMDs of the normal control subjects were shown in(Appendix 3). 
Four hundred and twenty-five nonnal Hong Kong Ghinese females and 163 
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normal Hong Kong Chinese males were recruited according to Hologic 
normal control standard protocol. 
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Chapter 4 Phase II: Fluoride in the treatment of 
osteoporosis 
4.1. Introduction 
The ideal treatment for osteoporosis is to increase bone density 
sufficiently to reduce the risk of fracture. Many of the currently used 
therapies act mainly by reducing the rate of bone loss, such as calcium, 
oestrogen, calcitonin and bisphosphonate. Fluoride is one of the many 
agents known to increase vertebral bone density. Its action on bone was 
noted from the observation that the trabecular bone density of the axial 
skeleton increased in fluoride poisoning cases. Moreover, a lower incidence 
of osteoporosis was observed in areas with high levels of fluoride in the 
drinking water(1-1.2 mg / liter) (Bernstein, D. S., Sadowsky, N. et al, 1966; 
Kroger, H., Alhava, E. et al, 1994; Cauley, J. A., Murphy, P. A. et al, 1995). 
Sodium fluoride is first used to treat vertebral osteoporosis(Rich, C. and 
Ensinck, J., 1961). Recently, several studies of sodium fluoride and di-
sodium monofluorophosphate combined with calcium supplements or vitamin 
D had been carried out(Reginster, J. Y., 1995). All showed that fluoride is an 
effective agent in increasing trabecular bone mass, but questions remain 
regarding the quality of the new bone and the efficacy of fluoride in 
decreasing the rate of vertebral fracture. In addition, its side effects are 
common. Moreover, cortical bones in fluoride treated patients were reported 
to be more fragile(Gutteridge, D. H., Price, R. I. et al, 1984). A four year 
placebo-controlled study on sodium fluoride carried out in U.S. shown that 
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there was an increase in BMD but fracture rates remain constant(Riggs, B. 
L., Hodgson, S. F. etal, 1990). 
A survey on the effect of fluoridated drinking water was conducted in 
Finland with 3222 postmenopausal women aged 47-59 years. A total of 969 
women who had used fluoridated drinking water (1.0-1.2 mg/l) for over 10 
years were compared with 2253 women with low levels of fluoride in drinking 
water (<0.3 mg/l). BMD of the lumbar spine was slight higher in the fluoride 
group, but the BMD of the femoral neck was similar between the two groups. 
There were no significant differences between the groups in the prevalences 
of self-reported fractures(Kroger, H., Alhava, E. et al 1994). 
4.2. Mechanisms of action 
4.2.1. Antiresorptive effect of fluoride 
Fluoride ions replace hydroxyl ions in the calcium hydroxyapatite 
crystals of bone to form fluoroapatites, which increase the crystallinity and 
reducing the solubility of bone minerals, making them more resistant to the 
resorptive processes(Moreno, E. C., Kresak, M. et al, 1977). 
4.2.2. Force-oriented osteogenic effect of fluoride 
Fluoroapatite produces stronger piezoelectric currents than that of the 
normal hydroxyapatite, thus stimulates more intensely the activation and 
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osteogenic activity of the osteoblasts along the line of mechanical 
forces(Bassett, C. A., 1968). 
4.2.3. Biochemical osteogenic effect 
Fluoride inhibits the osteoblast-specific acid phospho-tyr protein 
phosphatases and results in the building up of the phospho-tyr-proteins in 
the osteoblasts and enhances the mitogenic and bone forming activities of 
these cells(Lau, K. H., 1987). 
4.3. Effect of fluoride salts on BMD: results of clinical trials 
Oral ingestion of 50 to 80 mg sodium fluoride a day(22.6 mg to 36.2 
mg fluoride ion) increases bone mass by about 10 % a year in 8C)o/o of 
treated patients(Kelly, T. L., Slovik, D. M., et al, 1988; Riggs, B. L , Hodgson, 
S. F., et al, 1990; Devogelaer, J. P., Baudoux, C.. et al, 1992; Rizzoli, R., 
Chevalley, T. et al, 1995)(Table 4.1). There have been many studies 
showing conflicting results in vertebral fracture frequencies with different 
fluoride preparations. In a prospective two-year study, patients treated with 
fluohde(50 mg NaF a day) showed a significantly lower rate of new vertebral 
fractures compared with patients having a variety of other commonly used 
treatments(Mamelle, N., Meunier, P. J. et al, 1988). A four-year study 
revealed that ve「teb「al fracture「ate was not affected by fluoride intake(75 
mg a day supplemented with 1500 mg calcium), but nonvertebral fracture 
rate was significantly increased by three folds 丨门 the treatment group(Riggs, 
B. L., Hodgson, S. F., et al, 1990). Moreover, BMD increased by 35 %, 12 % 
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and 10 % at the lumbar spine, femoral neck and trochanteric area 
respectively over the study period, but the BMD decreased by 4% at the 
shaft of the radius. Fifty women from this sodium fluoride group were 
followed for further two years with a reduced dose of fluoride. In these 
women, vertebral fracture rate was reduced and BMD was increased by 8.7 
o/o over the six-year period(Riggs, B. L., WM,〇 .F., et al, 1994). It appears 
that high vertebral fracture rate was associated with high fluoride doses and 
low fluoride doses resulted in lower vertebral fracture rate. 
4.4. Effect of fluoride on bone histomorphology 
Histomorphology studies showed bone fluoride content increased with 
the length of fluoride ingestion. Trabecular osteoid surfaces were increased 
by 96% without significant increase in trabecular resorption surfaces in one 
French study on postmenopausal female and male with at least one non-
traumatic vertebral crush fracture(Meunier, P. J., 1990). One study showed 
5.4 o/o increase in bone apposition rate at lumbar spine{L2-L4), and 23.5 % 
decrease in trabecular space in postmenopausal women and men with 
known mild osteoporosis treated with 50 mg slow-release sodium fluoride 
and 50 pg 25-hydroxyvitamin D3 supplement a day for two years(Zerwekh, J. 
E., Hagler, H. K. et al, 1994). In contrast, bone biopsies obtained from a 4-
year study with 75 mg NaF and 1500 Ca mg/day showed no significant 
difference in mineral apposition rate between fluoride treated group and 
placebo treated group. The bone fluoride content rose throughout the 
I 
treatment period. Anyhow, evidences for fluoride induced osteomalacia were 
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observed from prolonged mineralization lag time, increased osteoid 
thickness, and defects in mineralization(Lundy, M. W., Stauffer, M., et al, 
1995). 
4.5. Compliance with sodium fluoride therapy 
NaF could be effective in the treatment of bone loss, but it is 
incompatible with calcium supplements or with calcium rich meals, because 
they combine and form CaF2, which is practically insoluble and impedes the 
absorption of fluoride in the gastrointestinal tract. Patient compliance is 
reduced by the formation of the gastrointestinal irritant hydrofluoric acid, the 
development of peripheral pain syndrome, the incidence of occasional 
vomiting( in 30 % of patients) and stress fracture(Mamelle, N., Meunier, P. 
J., et al, 1988). Recently, several studies have reduced some of the above 
complications by using a time released monofluorophosphate (MFP) 
preparation(Delmas, P. D., Dupuis, J. et al, 1990; Rizzoli, R., Chevalley, T., 
et al, 1995; Sebert, J. L., Richard, P. et al, 1995) or slow-release preparation 
of fluoride{Zerwekh, J. E., Hagler, H. K.. et al, 1994). 
4.6. Contradiction of fluoride treatment 
I 
The major side-effect of fluoride therapy is the possible increase in 
the fractures of the peripheral skeleton. Occurrence of such fractures may be 
reduced with lower fluoride dose. Both animal and human studies showed 
that, it may「educe bone mineralization and decrease the strength of bone at 
i 
higher doses of fluoride. This may explain why many of the patients treated 
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with fluoride have an extremely low hip bone density(Table 4.1), which may 
「esult in increased fracture risk. This risk may be further enhanced once the 
osteogenic responses begin in the presence of calcium malabsorption, and 
result in skeletal bone loss. Bone biopsy in one study revealed 75 mg 
sodium fluoride a day for 4 years induced osteomalacia in osteoporotic 
patients(Riggs, B. L, Hodgson, S. F., et al, 1990). This might be due to the 
strong fluoride stimulation for bone formation that cause calcium deficiency 
and such calcium deficiency might be the possible factor for stress 
fractures(Lmdy, M. W., Stauffer, M., et al, 1995). 
4.7. Sodium monofluorophosphate preparation 
Sodium monofluorophosphate is a non-toxic fluoride preparation has 
fewer side-effects than sodium fluoride. Sodium monofluorophosphate 
preparations often contained calcium to eliminate the risk of 
hypomineralization due to the intake of fluoride without calcium. In addition, 
Sodium monofluorophosphate preparations appear to be better tolerated, 
with a significant decrease in gastric mucosal lesions(Muller, P., Schmid, K. 
et al, 1992). Moreover, it has been shown that, with similar fluoride content, 
sodium monofluorophosphate, due to its better intestinal absorption, 
compared with sodium fluoride, is more effective in stimulating trabecular 
bone formation(Delmas, P. D., Dupuis, J., et al, 1990). 
The bioavailability of fluoride in serum from oral ingestion of sodium 
monofluorophosphate was assessed in one study(Trautner, K. and Einwag, 
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J., 1987; Trautner, K. and Einwag, J., 1989). Aqueous solutions of sodium 
fluoride, monofluorophosphate (Na2FPO3, MFP) and MFP containing 
tabiets(Caflu, Tridin) were given to fasting healthy volunteers. Serum fluoride 
profile and urinary fluoride output were found to be identical for all cases. On 
a follow-up experiment, Caflu was given together with milk, breakfast, 
breakfast and milk, or on a fasting stomach. The fluoride bioavailability was 
found to be reduced by 28% in the milk only group, 22% in the milk and 
breakfast group, and there was no difference between the fasting and 
breakfast only g「oup. This suggested bioavailability of fluoride is greatly 
affected by the formation of calcium salts and prolonged stay of calcium salts 
in the chyma after ingestion allow fluoride to be released by digestive 
processes. 
In a controlled study(Rizzoli, R., Chevalley, T., et al, 1995), forty-eight 
co「ticoste「oid-induced osteoporosis patients were divided into two groups. 
Patient characteristics of mean age, year after menopause(for women), 
fracture history, BMI, duration and mean daily doses of prednisone were 
similar. The treatment group consisted of 13 male and 12 female received 
sodium monofluorophosphate (26 mg fluoride) and 1000 mg calcium a day, 
and the control group consisted of 10 male and 13 female received only 
1000 mg calcium a day, they both are followed up for 18 months. Lumbar 
spine BMD in the fluoride-calcium group increased by 7.8 土 2.2 % compared 
with 3.6 土 1.3 o/o in those given calcium after 18 months. However, the BMDs 
of femoral neck and midfemoral shaft were lower in the fluoride-calcium 
treated group compared with the group given calcium alone. The changes in 
丨 33 
BMDs expressed as percent were -1.5 土 1.8 % versus +0.9 土 1.8 % for 
femoral neck, and -1.1 土 1.1 % versus -0.5 土 1.4.% for midfemoral shaft after 
18 months of follow-up in the monofluorophosphate-calcium treated group 
and the group given calcium alone, respectively. These results indicated that 
the combination of sodium monofluorophosphate and calcium were more 
efficient than calcium alone in increasing lumbar spine BMD in patients with 
corticosteroids-induced osteoporosis; neither femoral neck nor femoral shaft 
BMD was increased. 
In another prospective double-masked randomised study of 94 
osteoporotic patients aged 50-70(Sebert, J. L., Richard, P., et al, 1995), 
patients received 26.4 mg fluoride ion (200 mg sodium 
monofluorophosphate) and 1000 mg calcium ion, or placebo (1000 mg 
calcium ion) a day for two years. Lumbar spine BMD increased by 7.1 % per 
year in the fluoride treatment group and 71.4 % of the treated patients 
showed an increase in lumbar spine BMD of more than 0.034 g / cm^ 
compared with the control group. Gastric intestinal side effect was similar in 
the fluoride treated or control group(22 % to 18 %), but pain in the lower 
limbs was higher in the fluoride treated group(11 %) than in the control 
group(4 %). Tolerance was considered to be good and very good by more 
than 80 % of patients in each group. 
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Table 4.1 Summary f rom recent studies o f B M D with fluoride 
[nvestigator Equipment Population NaF a day Site Change in B M D Side effect 
MFP a day (%) Comments 
i _ s m a n，A . D P A 48 female 20-60mg NaF L2-L4 + 8 .4% 6 9 % F responders 
B. and Drost, age:63±10.1 year l g Ca Forearm - 7 .7% 2 1 % Gastric discoinfort 
D. J., 1989) 16 months 2 5 % Lower leg pain 
4 .% Fracture 
(Mamelle, N., N/A 257 male/ female 50mg NaF Spine N/F fell in fracture rate 
Meunier, P. J.， lg Ca 
etal, 1988) 800IU Vitamin D . 
：(Meys, E., QDR-1000 203 male/female 
Terreaux- Group l :>-1.5SD Ig Ca, 200mg MFP L2-4 +12.5 % / year 16% gastric discoinfort 
Duvert, F. et 1000 IU Calcidiol +29.5% / 2 y e a r 8% l o w e r l e g p a i n 
al, 1993) Group 2< -1.5SD Same as above 
• CPouilles, J. DPA 52 female 50 nig NaF L2-L4 + 5.5% / year 49% F responders 
M.， age: 60±5 lg Calcium Hip No change 29% gastric discoinfort 
Tremollieres, 400 IU Vitamin D2 4% lower leg pain 
F.，et al, 1991) 24 months 12% withdrawn 
‘O^zzoli, R., QDR-1000 48 subjects on 2(X)mg MFP L2-L4 +7.8 % / year Dietary Ca <400 mg/day 
！ Chevalley, T., corticosteroids > 1 lg Calcium Hip(neck) -1.5 % / year Similar to Hong Kong 
etal，1995) year Forearm -1.1 % / year OLau, E. M. and Cooper, 
C.，1993) 
lg Calcium only L2-L4 +3.6 % / year 
Hip(neck) +0.9 % / year 
Forearm -0.5 % / year 
丨 35 
Table 4.1 (Continue) 
[nvestigator Equipment Population NaF a day Site Change in Side effect 
B M D (o/o) MFP a day Comments 
i;Riggs, B. L. ,~~Unknown 202, white female 75 mg NaF LS +8.2 % / year Side effect 
Hodgson, S. 
P e ta i 1990) Age:50-75 1.5 g calcium Hip(neck) +1.8 % / y e a r 65 % for 4 year in NaF 
'， ’ . group and 26 % for 4 
postmenopausal Hip(IiUer) -1.8 % / year y^ar in calcium group 
With known Forearm -1.8 % / y e a r 
fracture 
Length ofstiidy: 4 
yg^j. 1.5g calcium LS +0.4 % / year 
Hip(neck) - 0 . 9 % / y e a r 
Hip(Inter) ' - 0 . 7 % / y e a r 
Fo rea rm -0.4 % / yea r 
(Thiebaud, D., QDR-1000 16 female 20-30 nig F" a L2-L4 + 1 2 . 0 % / 2 year L2-L4 + 3 % / 6 m o n t h s 
Burckhardt, P. 
2t al, 1994) age: 67 day Hip(neck) -0.5 % / 2 year 
lg Calcium Forearm -1.3 % / 2 year 
(Zerwekli, J. D X A 23 male and 50 nig Slow- L2-L4 +8.3 % in serve Increase in Lumbar spine 
E.’ Hagler, H. female with one or release NaF osteoporotic B M D 
K., et al, more vertebral . case at start 
1994) fracture 50 [ig Vitamin Increase in mineral 
D3 +3.4 % in mild apposition rate 
_ osteoporotic 
1.5g calcium case at start Increase in bone fluoride 
contain 
decrease in trabecular 
spacing 
* = Hip(intertrochanteric region) 
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Chapter 5 Phase II: The effects of fluoride on 
bone mineral density of OAD patients 
on steroid treatment 
5.1. Objectives 
To study if daily oral administration of 20 mg monofluorophosphates 
(plus 600 mg calcium) will increase BMDs at the hip and spine in chronic 
asthmatic subjects, who are on inhaled steroid therapy of 800 \jg - 4000 pg 
per day. 
5.2. Subjects and methods 
5.2.1. Power of the study 
In order to detect a statistical difference of 0.8 with a power of 
0.75 and type I e「「o「of 5% between treatment and the control groups. The 
minimum number of patients required in each group is 20. 
5.2.2. Subjects 
Disease definition and selection criteria 
Patients who fulfilled the following criteria were studied:-
！ 
I j 
a) Diagnosed to have chronic obstructive airway diseases or 
asthma by a qualified physician, and were taking inhaled 
steroids(> 800 j^g / day). 
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b) Aged 18 years and over. 
c) Have never had a history of metabolic bone disease. 
Patients were recruited from the Specialist Respiratory Disease Clinic 
at the Prince of Wales Hospital. All eligible patients who were registered with 
the clinic were recruited. The trial was conducted from January 1995 to 
December 1995. 
5.2.3. Method of randomisation 
To ensure equal number of patients allocated to each treatment 
group. Three permuted blocks A,已 and C were generated by a computing 
program. In brief, each block contained 40 cells(5 by 8 cells), Each 
participate of that group assigned a of letter F (Tridin) or P (Calcium) 
randomly. The order of assigning a patient to the blocks were from the left to 
the right and then the top to the bottom(Table 5.1). However, the distribution 
of age and BMI we「e widely scatter, since the BMDs are affected by 
advanced age. In order to minimise the confounding effects of age, sex and 
BMI on the BMDs in this phase of study, the OAD patients taking Tridin or 
calcium from each block were matched according to age, sex and BMI. 
Finally, forty one sex, age and BMI matched pairs were formed and the data 
of the unmatched subjects were not analysed in the study. 
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5.2.4. Treatment modalities 
5.2.4.1. Treatment group 
The treatment group was prescribed two Tridin tablets twice a day, to 
be taken before breakfast and going to bed. The tablets were chewed and 
swallowed with a glass of water. Each tablet contained the following active 
ingredients: L-gluatamine monofluorophosphate 134 mg, calcium D-
gluconate monohydrate 500 mg, and calcium citrate tetrahydrate 500 mg, 
equivalent to 5 mg fluoride and 150 mg calcium. The total drug intake was 
thus 20 mg fluoride and 600 mg calcium per day for the treatment group. 
5.2.4.2. Control group 
The control group was prescribed identical tablets with similar 
constituents to the treatment group except for the monofluorophosphates. 
The frequency and mode of intake were similar to the treatment group. The 
total drug intake was 600 mg elemental calcium per day for the control 
group. 
5.2.5. Bone mineral density measurements 
The outcome measurements were percentage changes in bone 
mineral densities at the hip and spine as measured by dual X-ray 




Bone mineral density was measured at the beginning of the trial and 
after nine months follow up. For subjects who had drug treatment less than 
nine months but intended to drop out of the trial, a BMD measurement was 
taken before they exited. 
5.2.6. Routine quality control of measurement and precision on patient 
repositioning 
The procedures have been described in sections 3.2.5.3 and 3.2.5.4. 
5.2.7. Methods of monitoring drug compliance 
Subjects were followed up at the respiratory clinic every 4-6 weeks. 
During their visit, a researcher asked them in details about the happenings 
of side effects and their compliances of drug intake. Ten to twenty extra 
tablets were prescribed at each visit and the remaining tablets that the 
subjects brought back were counted to monitor their compliances. 
5.2.8 Statistical methods 
Chi-square test and paired t-test were applied to compare lifestyle 
factors between the treatment and control groups at the beginning of the 
trial. The percentage changes in BMDs of the total body, lumbar spine, 
femoral neck, intertrochanteric region and Ward's triangle between the 
t 
Tridin and control group were compared by paired t-test. 
4 0 
’ 
Table 5.1. Permutation blocks to show the assignment of OAD patients to 
I 
the Tridin or the calcium treatment groups 
Block A: Pre-menopausal women on inhaled steroids 
~ ~ 1 2 3 4 5 6 7 ~ ‘ 8~~~ 
1 ~ P F P P F P F F “ 
2 F F P F F P P P 
3 P F F F F P P P 
4 F F F F P P P p 
5 P F F P F F P P 
Block B: Post-menopausai women on inhaled steroids 
~ " 1 2 3 4 5 6 7 8 “ 
1 ~ F F F F F P P p ~ 
2 P P F P F P F F 
3 F F P F P F P P 
4 P F P F F P F P 
5 F P F P P P F P 
i Block C: Men on inhaled steroids 
“ 1 2 3 4 5 6 7 8 ~ 
1 ~ F F F P P F P p ~ 
2 P F F F F P F F 
3 F P P P F P F F 
4 P F F P F P P F 
5 F F F P F P P p 
..1 
1 
丨 P = Calcium F = Tridin 
Assignment order: A1/1,A1/2, A1/3, A1/4, A1/5, A1/6, A1/7, A1/8, B1/1 etc. 
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Chapter 6 Results for phase I 
6.1. Statistical power of this phase of the study 
The statistical power of this phase of the study was summarised as 
below: 
A B C D E F 
~d^ ^ ^ 0 ^ ^ 0 ^ O M ~ ~ 
(n) 37 36 14 33 24 24 
Power 0.75 0.75 0.65 0.7 0.7 0.7 
A: Pre-menopausal 〇AD women on inhaled steroids and controls 
B： Post-menopausal 〇AD women on inhaled steroids and controls 
C: Post-menopausal 〇AD women not on inhaled steroids and controls 
D: OAD men on inhaled steroids and controls 
E: OAD men not on inhaled steroids and controls 
F: OAD men and Women not on inhaled steroids and controls 
n： Number of matched pairs 
dr: Magnitude of difference to be detected between the two groups 
Groups A, B and D had statistical power of 0.75. 0.75 and 0.7, 
respectively, group C had a statistical power of 0.65, and group E and F had 
statistical power of 0.7. The power was affected by the sample size, the 
smaller the small size the lower of the power. 
6.2_ Clinical features of OAD subjects on inhaled steroid 
One hundred and forty-four OAD men and women were recruited, of 
whom 106 were on inhaled steroids and 38 were not on inhaled steroids. For 
those 106 OAD patients on inhaled steroids: They were stratified into: Group 
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A consisted of 37 pre-menopausal women, group B consisted of 36 post-
menopausal women and group D consisted of 33 men, among these OAD 
patients on inhaled steroid, seven, nine and ten had used oral steroid in the 
past. For those 38 OAD patients not on inhaled steroids, they were stratified 
into: Group C consisted of 14 post-menopausal women and group E 
consisted of 24 men. Group F consisted of 24 age, sex and BMI matched 
pairs of OAD patients on or not on inhaled steroids(Chart 6.1). 
Chart 6.1 Stratification for OAD patients 
144 OAD (on or not on inhaled steroids) 
/ \ 
106 OAD patient were 38 OAD patients were 
on inhaled steroids not on inhaled steroids 
/ 1 \ / \ 
37 premeno- 36 postmeno- 33 men 14 post meno- 24 men 
pausal women pausal women pausal women 
(Group A#) ( G r o u p B # ) (Group D#) (Group C#) (Group E#) 
^ ^ ^ • 
； 7 postmeno- 17 men 7 post meno- 17 men 
pausal women pausal women 
\ ^ " v ^ 
T ^ 
24 OAD on inhaled steroids 24 OAD not on inhaled steroids 
j I 1 
:l i 
) (Group F: 24 pairs of age, sex, and BMI matched OAD patient on or not on inhaled steroids) 
； # For each OAD patients, two age, sex, and BMI matched control subjects were recruited 
I •| 
丨 For each OAD patient, their BMDs and body compositions were 
compared with two age, and BMI matched normal control subjects. There 
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were signif icant dif ferences among some of the demographic and basel ine 
characterist ics as set out in table 6.1a to 6.1f, 
Smokers and drinkers were predominately found among older male 
patients and their control subjects with or without the use of inhaled 
steroids(Table 6.1d-e). Compared with the normal control subjects, there 
were statistically significant more smokers and drinkers among the OAD 
patients. Moreover, exposure to cigarette smoke measured as pack years 
were significantly greater in the OAD patients than in their matched control 
subjects. 
Daily dietary calcium intake among the whole study groups and 
normal control subjects ranged from 197 to 324 mg / day(Table 6.1c). There 
were no statistical differences in most groups except the OAD post-
menopausal group, where the calcium intake in the control group(324 土 6 9 
. i 
mg I day) was higher than the patients(197 土 125 mg / day) (p<0.05)(Table 
6.1.c). 
： ! 1 
j The age of menarche in the pre-menopausal women(Table 6.1a) was 
！ I ！ 
14 years old compared to 16 to 17 years old in the post-menopausal 
j 
groups(Table 6.1b-c). The age of menopause among post-menopausal 
women was around forty-six to forty-eight years old(Table 6.1b-c). 
Past history of using oral contraceptive was significantly higher in the 
OAD pre-menopausal women when compared with the pre-menopausal 
control subjects(Table 6.1a), and there were fewer oral contraceptive users 
among post-menopausal women control subjects(table 6.1b-c). 
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6.3. Anthropometric measurements and bone mineral density 
The body compositions and bone mineral densities of the five study 
groups were presented in table 6.2a-6.2e, and the differences in bone 
mineral density between the OAD patients on inhaled steroids and the OAD 
patient not on inhaled steroid were presented in table 6.2f. 
Significant differences in body height(p<0.01), body mass 
index(p<0.001), fat mass(p<0.01) and percentage of body fat(0.001) 
between the pre-menopausal OAD women on inhaled steroids and their 
controls were found(table 6.2a). The BMD of the total body(p<0.05) was 
significant lower in pre-menopausal OAD women taking inhaled steroid, 
j However, this significance was removed after adjustment for confounding 
factors(Table 6.3.a). 
In the group of post-menopausal OAD women on inhaled 
steroids(tab!e 6.2b), significant differences in body mass index(p<0.05) and 
• 1 j 
! fat mass(p<0.05) were found. The BMD at the lumbar spine(L1-L4)(p<0.01) 
! 
j was significant lower in postmenopausal OAD women taking inhaled steroids 
j than their matched controls. However, this significance was removed after 
adjustment of confounding factors(Table 6.3b) 
•i : : I 
• 1 
i In the group of post-menopausal 0>^D women not on inhaled 
steroids(table 6.2c), no significant differences were found for any of the 
anthropometric measurements and bone mineral densities. 
In the group of OAD men on inhaled steroids(table 6.2d), significant 
difference in body weight was noted(p<0.05). The BMDs of the lumbar 
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spine(p<0.01), femoral neck(p<0.05), intertrochanteric region(p<0.01) 3nd 
Ward,s triangle(p<0.05) of the patients were also significantly lower than 
those of the controls. However, after adjustment of confounding factors, 
none of the above BMDs remained statistically significant. 
In the group of OAD men not on inhaled steroids(table 6.2e), 
significant differences between the treatment and control groups were found 
for body weight, body height and lean body mass(p<0.05). The BMDs of the 
total body(p<0.05), lumbar spine(p<0.05), femoral neck(p<0.001), 
intertrochanteric region(p<0.001) and Ward's triangle(p<0.01) were 
significantly lower among the patient group. After adjustment for confounding 
factors, BMDs of the femoral neck, intertrochanteric region and Ward's 
triangle remained statistically significant(Sig of F < 0.05)(Table 6.3e.). 
Comparing the OAD patients (men and women) on inhaled steroids 
and those not on inhaled steroids, no significant difference was found for all 
( 
I the anthropometic measurements taken between the two groups. Only the 
BMD of lumbar spine was found significant lower in the group taking inhaled 
steroids(p<0.05)(Table 6.2.f). After adjustment for confounding factors, the 
lumbar spine BMD remained statistically significant(Sig of F <0.05). 
The fat mass was similar between the premenopausal 3nd 
postmenopausal women on inhaled steroids(23 土 9 kg and 25 土 8 kg, 
respectively)(Table 6.2a-b), and their fat masses were statistical significantly 
higher than their age matched normal control subjects(Table 6.2a，p<0.05; 
table 6.2b’ p<0.01). However, the OAD women not on inhaled steroids did 
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not show increased body fat mass compared with their age matched 
controls(table 6.2c). 
For the OAD men, there were no statistically significant differences in 
fat mass and percentage of body fat among subjects taking inhaled steroids 
(table 6.2d), those not taking inhaled steroids(Table 6.2e) and their age and 
BMI matched control subjects. 
The lean body mass was not significantly difference between most of 
the patient groups and their age matched control, except for the OAD men 
not on inhaled steroids who had lower lean body mass than their normal 
control subjects(Table 6.2.e.). 
.| 
I In this study, the men patients had higher lean body mass and lower 
i 
fat mass than the women patients(Table 6.2.a-c). The older patients(Table 
6.2d-f) had lower fat mass than the young patients(Table 6.2.a.). The lean 
i 
body masses among women patients were similar{Table 6.2.a-c.). 
The overall BMDs of all the case and control subjects decrease with 
advancing aging. The women had lower BMD than the men, and the young 
women had higher BMDs than the old women. Also, the OAD men had lower 
BMDs than their control subjects. 
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6.4. Analysis of covariance for BMDs differences 
The analysis of covariance for BMDs differences between the OAD 
patients and their matched normal controls adjusted for body height, body 
weight, cigarette pack year, alcohol intake per week, dietary calcium intake 
per day and load bearing exercise per week were performed and the results 
were shown in tables 6.3a to 6.3f. 
In table 6.3a’ the adjusted means of BMDs of the total body, lumbar 
spine， femoral neck, intertrochanteric region and Ward's triangle of the 
premenopausal women OAD patients on inhaled steroids were similar to that 
of their age and BMI matched normal controls. 
i 




I spine, femoral neck, intertrochanteric region and Ward's triangle of the 
I 
.i 
！ postmenopausal women on inhaled steroids were lower than those of the 
age and BMI matched controls. However, the differences were not 
statistically significant. 
In table 6.3c, the adjusted means of BMDs of the total body, lumbar 
spine, femoral neck, intertrochanteric region and Ward's triangle of the 
postmenopausal women who were not on inhaled steroids were lower than 
that of the age and BMI matched controls. However, the differences were not 
statistically significant. 
In table 6.3d, the adjusted means of BMDs of the total body, lumbar 
spine, femoral neck, intertrochanteric region and Ward's triangle of the OAD 
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i 
men on inhaled steroids were lower than that of the age and BMI matched 
controls. However, their differences were not statistically significant. 
In table 6.3e, the adjusted means of BMDs of the femoral neck, 
intertrochanteric region and Ward's triangle of the OAD men who were not 
on inhaled steroids were statistically significantly lower than that of their age 
and BMI matched controls(Sig of Fs <0.05). However, the differences of the 
adjusted means of BMDs of the total body and lumbar spine were not 
statistically significant. 
In table 6.3f, the adjusted means of BMDs of the lumbar spine of the 
OAD men and women who were taking inhaled steroids were statistically 
i j 
significant lower than those of the OAD men and women who were not taking 
inhaled steroids(Sig of F <0.05). However, the differences of the adjusted 
means of BMDs of the femoral neck, intertrochanteric region and Ward's 




6.5. Multiple regression 
Multiple regression was conducted to study the relative importance of 
the following factors in determining the BMD of the OAD patients: age, sex, 
duration of asthma, BMI, daily dietary calcium intake, cumulative dose of oral 
steroids, cumulative dose of inhaled steroids, current dose of inhaled 
steroids, and length of inhaled steroids use. 
The results of multiple regression against various variables of all 
OAD patients on inhaled steroids and the regression coefficients of the total 
BMD are shown in tables 6.3a to 6.3f. 
Age, sex, duration of asthma, BMI, daily dietary calcium intake, 
cumulative dose of oral steroids, cumulative dose of inhaled steroids, current 
dose of inhaled steroids and length of inhaled steroids were used as the 
independent variables, with lumbar spine BMD, total body BMD, femoral 
neck BMD, total body BMD. femoral BMD, hip intertrochanteric BMD and 
Ward's triangle BMD as the dependent variables. 
Age was the only factor negatively significant associated with lumbar 
spine BMD, femoral neck BMD, intertrochanteric and Ward's triangle BMD. 
In addition oral steroids usage was negatively associated with the femoral 










There were significant correlations among some of the anthropometric 
indices such as FEV1, height, lean body mass, body weight, fat content, past 
intake of oral steroids and BMD as set out in Appendix Table A.4. 
Bone mineral density decreased with increasing age(from r^  = -0.800 
for Ward's triangle to r' 二 -0.450 for total body BMD), duration of asthma, 
alcohol intake, age of menarche. and intake of oral steroids. 
Bone mineral density increased with increasing body weight, BMI, fat 
mass, lean mass, and lung function. 
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Table 6.1a: Demographic and baseline characteristics of the premenopausal OAD 
female patients on inhaled steroids and normal control subjects (mean 士 
SD) 
OAD on Normal 
Inhaled steroids Control 
H 74 
I 
i Age 36 土 7 36 土 1 
I Age of menarche 14 士 2 13 士 1 
Age of menopause N/A N/A 
Cumulative dose of oral steroids (mg) 95 士 255 N/A 
Oral steroid user (%) 
never 81 100 
ever 19 0 
Cumulative dose ofinhaled steroids (mg) 389 ± 180 N/A 
Duration of use ofinhaled steroids (week) 45 ± 17 N/A 
Current dose of inhaled steroids (|ag per 1411 士 713 N/A 
day) 
Average daily dose ofinhaled steroid (jig) 1310 士 569 N/A 
Daily dietary calcium (mg) 216 士 85 230 土 73 
Years ofdrinking among drinker(year) 4 土 0 2 士 0 
Alcohol drinking (%) 
never 97 99 
ever 3 j 
Alcohol intake among drinker (g/week) 52 士 0 13 士 0 
Cigarette smoking (%) 
never 97 95 
ever 3 5 
Years of smoking among smoker 4 士 o 7 士 5 
Cigarette pack year among smoker 1 土 o 2 士 1 
Load bearing exercise (hours/week) 0 士 1 1 士 i 
Ever use oral contraceptives (%) 
never 60 55 
ever 40 45 
Months of oral contraceptive use among 27 ± 33 60 士 61* 
oral contraceptive user 
Paired t-tests: 
* p < 0 . 0 5 
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Table 6.1b Demographic and baseline characteristics of the postmenopausal OAD 
female patients on inhaled steroids and normal control subjects (mean 士 
SD) 
i * " " ~ " " ~ ~ ~ ~ ~ ~ ~ " ~ " ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ " ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ * ^ ~ ~ ~ ~ ~ - ~ ~ « ~ ~ ~ « « ~ ~ ~ ~ « « p « « _ _ ^ _ « 
I f 
OAD on Normal 
I Inhaled steroids Control 
_36 72 
Age 64 士 9 64 士 9 
Age of menarche 16 士 2 16 士 2 
Age of menopause 48 士 5 49 士 4 
Cumulative dose of oral steroids (mg) 144 士 305 N/A 
Oral steroid user (%) 
never 75 • 
ever 25 0 
Cumulative dose ofinhaled steroids (mg) 592 士 221 N/A 
Duration of use ofinhaled steroids (week) 42 土 13 N/A 
Current dose ofinhaled steroids (^ig per day) 1522 土 508 N/A 
Average daily dose ofinhaled steroid (jag) 1446 土 425 N/A 
Daily dietary calcium (ing) 238 土 124 275 土 77 
Years ofdrinking among alcohol drinker(year) 3 ± 0 5 ± 0 
Alcohol drinking (%) 
never 89 99tt 
ever 11 1 
Alcohol intake among alcohol drinker 54 士 0 816 士 0 
(g/week) 
Cigarette smoking (%) 
never 67 93ttt 
ever 33 7 
Years ofsmoking among cigarette smoker 17 土 12 10 土 10 
Cigarette pack year among cigarette smoker 8 士 7 1 土 i 
Load bearing exercise (hour/week) 0 士 1 2 土 2** 
Ever use contraceptives (%) 
never 14 26 
• 86 74 
Months oforal contraceptive use among oral 13 士 16 9 土 io 
contraceptive user 
Paired t-tests: Chi-square test: 
, , ” p<0.01 




Table 6.1c Demographic and baseline characteristics of the postmenopausal OAD 
j female patients not on inhaled steroids and normal control subjects 
； (mean 土 SD) 
( 
i “ i 
i OAD female patient Normal 
！ not on inhaled Control 
‘ steroids 
； H 28 
\ 
- Age 75 士 5 75 士 5 
= Age of menarche 17 士 3 16 士 1 
I Age of menopause 46 士 5 50 土 5 
Intake of oral steroids (mg) N/A N/A 
Oral steroid user (%) 
never 100 100 
ever 0 0 
Daily dietary calcium (mg) 197 土 126 324 土 69* 
Years of drinking among drinker 2 士 1 0 土 0 
Alcohol drinking (%) 
never 86 100卞 
ever 14 0 
Alcohol intake among drinker (g/week) 55 士 51 0 士 0 
Cigarette smoking (%) 
never 14 64卞卞卞 
ever 86 36 
Years of smoking among cigarette smoker 24 土 13 20 土 11 
Cigarette pack year among cigarette smoker 7 士 6 10 士 9 
Load bearing exercise (hour/week) 0 士 0 0 士 0 
Ever use contraceptives (%) 
never 14 7 
ever 86 93 
Months of contraceptive use among oral 144 士 0 12 士 0 
contraceptive user 
•A 
I 4 ‘ 
^ 
I Paired t-tests Chi-square test: 
I * P < 0 . 0 5 t p<0.05 
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Table 6.1d Demographic and baseline characteristics of the OAD male patients on 
！ inhaled steroids and normal control subjects (mean 土 SD) 
i 
i 
" " ^ " " * " " " * " " " ^ " " " " " ^ " " " " * " ^ ^ ^ " " " " • ^ ^ ^ " • • • • * ^ " • • " * ^ " • " • " * * * ^ ^ ^ ^ ^ " • • * • • ^ ^ ^ • " * " • • " ^ ^ * • * ^ ^ ^ * • " • ^ ^ • * * • ^ ^ * • • " • * • • • • • • * “ * 
OAD male patient on Normal 
inhaled steroids Control 
^ 66 
Age 63 土 9 64 土 9 
Oral steroid user (%) 
never 70 100 
ever 30 0 
Cumulative dose of oral steroids (mg) 203 土 433 N/A 
Cumulative dose ofinhaled steroids (mg) 376 ± 153 N/A 
Duration of use ofinhaled steroids (week) 40 士 11 N/A 
Current dose ofinhaled steroids ([xg per day) 1333 士 502 N/A 
Average daily dose ofinhaled steroid (^g) 1374 土 445 N/A 
Daily dietary calcium (ing) 201 士 98 254 士 81* 
AJcohol drinking (%) 
never 42 61卞 
ever 58 39 
Years of drinking among alcohol drinker 25 土 14 20 士 13 
Alcohol intake among alcohol 81 士 57 867 土 635* 
drinker(g/week) 
Cigarette smoking (%) 
never 1 g 44ttt 
ever 82 56 
Years ofsinoking among cigarette smoker 37 士 10 27 士 19 
Cigarette pack year among cigarette smoker 32 土 26 19 士 17* 
Load bearing exercise (hour/week) 0 士 0 2 士 3 “ 
Paired t-tests: Chi-square test 
* P<005 t p<0.05 





I Table6.1e Demographic and baseline characteristics of the OAD male patients not 
I on inhaled steroids and normal control subjects (mean 士 SD) 
丨 OAD male patients Normal 
丨 not on inhaled steroids Control 
24 4S 
Age 70 士 7 71 土 7 
Intake of oral steroids (mg) N/A N/A 
Oral steroid user (%) 
never 100 100 
ever o 0 
Daily dietary calcium (mg) 211 士 118 255 土 82* 
Alcohol drinking (%) 
never 63 63 
ever 37 37 
Years of drinking among alcohol 53 土 11 24 土 5* 
drinker 
AJcohol intake among alcohol 9 6 士 1 0 1 3 7 3 6 ± 5 0 1 2 
drinker(g/week) 
Cigarette smoking (%) 
never o 33ttt 
ever 100 67 
Years of smoking among cigarette 50 士 13 30 土 1 6 _ 
smoker 
Cigarette pack year among cigarette 51 土 33 26 士 19" 
smoker 
Load bearing exercise (hour/week) 0 士 1 2 士 3* 
I ^ i r ed t-tests Chi-square test 
* P<0.05 ttt <0 001 
** p < 0 . 0 1 
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Table 6.1f Demographic and baseline characteristics of the OAD patients on inhaled 
steroids and OAD patients not on inhaled steroids(mean 士 SD) 
OAD patients OAD patients 
on inhaled steroids not on inhaled 
steroids 
^ 2A 
Sex (female/male) 7/17 7/17 
Age 69 土 5 70 土 6 
Age of menarche among female (year) 16 土 3 17 土3 
Age ofmenopause among female (year) 46 士5.1 46 土 4 
Peak flow rate (ml/min) 220 士87.0 262 士 104 
FVC 2 士 1 2 土 1 
FEV1 1 士 1 1 土 1 
Duration of OAD (year) 15 士 17 7 土 6* 
Oral steroid user (%) 
never 67 1 0 0 付 卞 
ever 33 0 
Cumulative dose of oral steroids (mg) 101 士 87 N/A 
Cumulative dose ofinhaIed steroids (mg) 416士 191 N/A 
Duration of use ofinhaled steroids (week) 42 士 12 N/A 
Current dose of inhaled steroids (|ag per 1375 士 535 N/A 
day) 
Average daily dose ofinhaled steroid (^g) 1410 士 492 N/A 
Daily dietary calcium (mg) 214 士 128 194 士 95 
Alcohol drinking (%) 
never 67 71 
ever 33 29 
Years of drinking among alcohol drinker 21 士 15 21 士 22 
AJcohol intake among alcohol 200 士 150 213 土 145 
drinker(g/week) 
Cigarette smoking (%) 
never 25 0付卞 
ever 75 100 
Years of smoking among cigarette smoker 35 士 12 40 士 16 
Cigarette pack year among cigarette 39 士 24 34 士 24 
smoker 
Load bearing exercise (hour/week) 0 士 0 0 士 1 
Ever use contraceptives % 
never 100 100 
ever o 0 
Paired t-tests: Chi-square test 
* P<0.05 ttt p<o.ooi 
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Table 6.2a: Anthropometric measurements and bone mineral density for 
premenopausal OAD female patients on inhaled steroids and control 
subjects(iTiean 土 S D ) 
OAD on inhaled steroids Normal control 
37 74 
Body measurement 
Weight (kg) 58 士 9 57 土 1 
Height (M) 1.5土 0.1 1.6士 0"* 
BMI (kg/H^) 25 士 3.6 23 土 3叫 
Fat mass (kg) 23 士 9 20 土 5* 
% ofbody fat (kg) 39 土 5 34 士 6叫 
Lean body mass (kg) 34 士 4 35 士 3 
Bone mineral density (giWcm^) 
Total body 1.012土0.07 1.046 士 0.035* 
Spine (Ll-L4) 0.949 士 0.11 0.984 士0.063 
Femoral neck 0.793 士 0.08 0.788 土0.067 
Intertrochanteric 1.067 ± 0 . 1 1 2 1.066 土0.095 
Ward'striangle 0 . 7 2 5 士 0 . 1 1 8 0 . 7 1 8 士 0 . 1 0 8 
Paired t-tests: 
* p < 0 . 0 5 
** p < 0 . 0 1 
*** p < 0 . 0 0 1 
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Table 6.2b: Anthropometric measurements and bone mineral density for 
postmenopausal OAD female patients on inhaled steroids and control 
subjects(mean 士 SD) 
OAD on steroids Normal Control 
n= 36 72 
Body measurement 
Weight (kg) 56 士 10 53 士10 
Height (M) 1.5士10 1.5士0 
BMI (kg/H') 25 士 4 24 士 3 
Fat mass (kg) 25 士 8 21 士 6* 
% o fbody fat (kg) 42 士 9 37 士 6 
Lean body mass (kg) 33 土 3 32 士 3 
Bone mineral density 
(gm/cm^) 
Total body 0.864 士 0.079 0.885 士0.094 
Spine (Ll-L4) 0.699 士 0.133 0.761 士0.132” 
Femoral neck 0.580 士 0.134 0.611 士0.091 
Intertrochanteric 0.804 ±0 .174 0.826 士0.136 
Ward's triangle 0.402 ±0.151 0.441 士0.118 
Paired t-tests: 
* p < 0 . 0 5 





Table 6.2c: Anthropometric measurements and bone mineral density for 
postmenopausal OAD female patients not on inhaled steroids and control 
subjects(mean 士 SD) 
OAD Patient Normal 
not on inhaled steroids Control 
n= 14 28 
Body measurement 
Weight (kg) 46 ± 9 48 士 7 
Height (M) 1.5士0 1.5士0 
BMI ( k g m ' ) 21 士 4 22 ± 3 
Fat mass (kg) 15 土 7 16 士 6 
% o fbody fat (kg) 31 士 12 33 土 8 
Lean body mass (kg) 30 士 3 31 士 2 
Bone mineral density (giWcm^) 
Total body 0.824 士0.066 0.827 土0.062 
Spine (Ll-L4) 0.639 士 0.088 0.683 ±0 .083 
Femoral neck 0.466 ± 0.182 0.534 ± 0.049 
Intertrochanteric 0.605 土 0.223 0.738 士0.095 
Ward'striangle 0 . 3 1 0 ± 0 . 1 5 4 0 . 3 3 9 士 0 . 0 6 8 
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I Table 6.2d: Anthropometric measurements and bone mineral density for OAD male 
j 
i patients on inhaled steroids and control subjects(mean 土 SD) 
i 
i i 
OAD on inhaled steroids Normal control 
n= 33 66 
Body measurement 
Weight (kg) 57 士9 61 士6* 
Height (M) 1.6土0 1.6士0 
BMI (kg/H') 22 土 3 23 士 2 
Fat mass (kg) 14 士 6 15 土 6 
% o fbody fat (kg) 25 土 6 23 士 5 
Lean body mass (kg) 42 士 1 44 士 6 
Bone mineral density 
(gm/cm^) 
Total body 0.995 ± 0.095 1.035 ±0 .058 
Spine ( L l - L 4 ) 0 .819 士0.131 0 .917 土0.103“ 
Femoral neck 0.637 士 0.105 0.702 ± 0.080* 
Intertrochanteric 0.880 士 0.160 0.991 士0.105“ 
Ward'striangle 0.448 土0.118 0.510 ±0.091* 
Paired t-tests: 
* p < 0 . 0 5 
** p < 0 . 0 1 
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Table 6.2e: Anthropometric measurements and bone mineral density for OAD male 
patients not on inhaled steroids and control subjects(mean 土 SD) 
OAD patient not on Normal 
inhaled steroids Control 
n= 24 48 
Body measurement 
Weight (kg) 56 士 10 60 士 8* 
Height (M) 1.6士 0 1.6土 0 
BMI (kgm') 22 土 4 23 土 3 
Fat mass (kg) 13 士 7 15 士 5 
% ofbody fat (kg) 22 士 9 23 士 5 
Lean body mass (kg) 41 士 5 43 土 4* 
Bone mineral density 
(gin/cm^) 
Total body 0.983 士0.065 1.019 ±0.065* 
Spine (Ll-L4) 0.868 ± 0.114 0.931 士0.106* 
Femoral neck 0.591 士 0.078 0.683 士 0.085州 
Intertrochanteric 0.840 土 0.125 0.980 士0.106*“ 
Ward'striangle 0.382 ± 0.083 0.474 士0.100" 
Paired t-tests: 
* p < 0 . 0 5 
** p < 0 . 0 1 
*** p < 0 . 0 0 1 
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Table 6.2f: Anthropometric measurements and bone mineral density for OAD patients 
on inhaled steroids and OAD patients not on inhaled steroids(mean 士 SD) 
OAD patients OAD patients 
on inhaled steroids not on inhaled steroids 
24 24 
Female / male 7/17 7/17 
Body measurement 
Weight (kg) 53 士 7 53 士 9 
Height (M) 1.6± 0 1.6士 0 
BMI (kg/H^) 22 士 3 22 士 4 
Fat mass (kg) 16 土 6 16 士 7 
% o fbody fat (kg) 28 士 10 28 士 10 
Lean body mass (kg) 39 士 5 39 士 6 
Bone mineral density (gin/cm^) 
Total body 0.923 土0.103 0.937 士0.080 
Spine (Ll-L4) 0.734 士0.142 0.800 土0.136* 
Femoral neck 0.570 士 0.125 0.584 士0.079 
Intertrochanteric 0.800 士0.187 0.794 士0.107 
Ward's triangle 0.369 士 0.130 0.392 土0.085 
Paired t-tests: 
* p < 0 . 0 5 
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Table 6.3a. Analysis of covariance results for BMDs differences between OAD 
premenopausal women on inhaled steroids and matched normal controls 
adjusting for body height, body weight, cigarette pack year, alcohol intake 
per week, dietary calcium intake per day and load bearing exercise 
BMD Source of variation Sum ofsquare DF MS F S i g o f F 
Total body Within + residual 0 ^ ^ O o 一 
Regression 0.03 6 0.00 1.04 0.400 
OAD/Normal control 0.02 1 0.02 3.56 0.060 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 1.012 1.013 1.012 
Normalcontrol 1.045 1.044 1.045 
Lumbarspine Within + residual 0.96 103 0.01 
Regression 0.13 6 0.02 2.25 0.040 
OAD/Normal control 0.03 1 0.03 3.24 0.075 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.949 0.949 0.949 
Normal control 0.984 0.985 0.984 
Femoral neck Within + residual 1.43 103 0.01 
Regression 0.17 6 0.03 2.09 0.061 
OAD/Normal control 0.00 1 0.00 0.06 0.803 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
OAD 0.793 0.788 0.793 
Normal control 0.776 0.781 0.776 
Intertrochanteric Within + residual 1.43 102 0.01 
Regression 0.25 6 0.04 2.92 0.011 
OAD/Normalcontrol 0.00 1 0.00 0 . ” 0.746 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
OAD 1.067 1.062 1.067 
Normalcontrol 1.065 1.070 1.065 
Ward's triangle Within + residual 1.45 102 0.01 
Regression 0.16 6 0.03 1.82 0.102 
OAD/Normal control 0.00 1 0.00 0.35 0.556 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
〇AD 0.725 0.719 0.725 
Normal control 0.728 0.734 0.728 
Obs mean = observed mean ~ ‘ “ 
Adj. mean = adjusted mean 
Est. mean = estimated mean 
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Table 6.3b. Analysis of covariance results for BMDs differences between OAD postmenopausal women 
on inhaled steroids and matched normal controls adjusting for body height, body weight, 
cigarette pack year, alcohol intake per week, dietary calcium intake per day and load 
bearing exercise 
BMD Source of variation Sum of square DF MS F S i g o f F 
Total body BMD~~Within + residual ^ ^ o ^ 
Regression 0.17 6 0.03 3.15 0.008 
OAD/Normal control 0.01 1 0.01 0.78 0.380 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
COAD 0.864 0.868 0.864 
Normal control 0.894 0.890 0.894 
Lumbarspine Within + residual 1.62 100 0.02 
Regression 0.76 6 0.13 7.86 0.000 
COAD/Normal control 0.06 1 0.06 3.72 0.057 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.699 0.702 0.699 
Normal control 0.761 0.757 0.761 
Femoralneck Within + residual 0.89 100 0.01 
Regression 0.63 6 0.10 11.7 0.000 
1 
OAD/Normal control 0.01 1 0.01 1.16 0.284 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
OAD 0.580 0.584 0.580 
Normalcontrol 0.611 0.607 0.611 
Intertrochanteric WKhin + residual 2.11 100 0.02 
Regression 1.12 6 0.19 8.82 0.000 
OAD/Normalcontrol 0.00 1 0.00 0.19 0.661 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.804 0.808 0.804 
Normal control 0.826 0.822 0.826 
Ward's triangle Within + residual 1.43 100 0.01 
Regression 0.78 6 0."l3 9.09 0 000 
OAD/Normal control 0.01 1 0.01 0.41 0.524 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
OAD 0.402 0.413 0.402 
Normal control 0.441 0.430 0.441 
Obs mean = observed mean ‘ “ ‘ 
Adj. mean = adjusted mean 
Est. mean = estimated mean 
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Table 6.3c. Analysis of covariance results for BMDs differences between OAD postmenopausal women 
not on inhaled steroids and matched normal controls adjusting for body height, body weight, 
cigarette pack year, alcohol intake perweek, and dietary calcium intake perday 
BMD Source of variation Sum ofsquare DF MS F S i g o f F 
Total body BMD~~Within + residual 0 ^ 35 O0^ 
Regression 0.04 5 0.01 1.35 0.266 
OAD/Normal control 0.00 1 0.00 0.65 0.427 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.824 0.812 0.824 
Normal control 0.827 0.839 0.827 
Lumbarspine Within + residual 0.47 35 0.01 
Regression 0.09 5 0.02 1.42 0.243 
OAD/Normalcontrol 0.01 1 0.01 1.00 0.325 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.639 0.636 0.639 
Normal control 0.683 0.686 0.683 
Femoral neck Within + residual 0.46 35 0.01 
Regression 0.12 5 0.02 1.83 0.132 
OAD/Normalcontrol 0.02 1 0.02 1.79 o.190 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.466 0.466 0.466 
Normal control 0.534 0.533 0.534 
Intertrochanteric Within + residual 0.36 34 0.01 
Regression 0.32 5 0.06 5.99 0.000 
OAD/Normal control 0.02 1 0.02 2.23 0.145 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
OAD 0.652 0.661 0.652 
Normal control 0.738 0.729 0.738 
Ward's triangle Within + residual 0.26 34 0.01 
Regression 0.12 5 0.02 3.18 0 018 
OAD/Normal control 0.00 1 0.00 0.49 0.490 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
〇AD 0.333 0.323 0.333 
Normal control 0.339 0.350 0.339 
Obs mean = observed mean ~ ‘ “ 
Adj. mean = adjusted mean 
Est. mean = estimated mean 
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Table 6.3d. Analysis of covariance results for BMDs differences between OAD men on inhaled steroids 
and matched normal controls adjusting for body height, body weight, cigarette pack year, 
alcohol intake per week, dietary calcium intake per day and load bearing exercise 
BMD Source of variation Sum ofsquare DF MS F S i g o f F 
Total body BMD~~Within + residual 0 ^ 79 o.01 
Regression 0.15 6 0.02 4.33 0.001 
OAD/Normal control 0.00 1 0.00 0.10 0.752 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
COAD 0.995 1.010 0.955 
Normalcontrol 1.031 1.016 1.031 
Lumbarspine Within + residual 1.33 89 0.01 
Regression 0.50 6 0.08 5.63 0.000 
COAD/Normalcontrol 0.03 1 0.03 1.88 0.174 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
OAD 0.819 0.845 0.819 
Normalcontrol 0.913 0.887 0.913 
Femoral neck Within + residual 0.76 89 0.01 
Regression 0.41 6 0.07 8.06 0.000 
OAD/Normal control 0.00 1 0.00 0.47 0.494 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.637 0.662 0.637 
Normal control 0.703 0.678 0.703 
Intertrochanteric Within + residual 1.27 89 0.01 
Regression 0.78 6 0:13 9.13 0.000 
OAD/Normalcontrol 0.03 1 0.03 2.29 0 134 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
〇AD 0.880 0.913 0.880 
Normal control 0.991 0.958 0.991 
Ward's triangle Within + residual 1.00 89 0.01 
Regression 0.39 6 0.07 5.81 0 000 
OAD/Normal control 0.00 1 0.00 0.01 0.914 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
OAD 0.448 0.477 0.448 
Normal control 0.509 0.480 0.509 
Obs mean = observed mean ‘ “ ‘ 
Adj. mean = adjusted mean 





Table 6.3e. Analysis of covariance results for BMDs differences between OAD men not on inhaled 
steroids and matched normal controls adjusting for body height, body weight, cigarette pack 
year, alcohol intake per week, dietary calcium intake per day and load bearing exercise 
BMD Source of variation Sum of square DF MS F S i g o f F 
Total body BMD~~~Within + residual 0 ^ ^ 0 ^ 
Regression 0.09 6 0.01 2.77 0.018 
OAD/Normalcontrol 0.01 1 0.01 2.32 0.133 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
COAD 0.983 0.984 0.983 
Normalcontrol 1.018 1.017 1.018 
Lumbarspine Within + residual 1.17 65 0.02 
Regression 0.15 6 0.03 1.41 0.226 
COAD/Normal control 0.04 1 0.04 2.14 0.148 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.868 0.872 0.868 
Normal control 0.936 0.932 0.936 
Femoral neck Within + residual 0.50 65 0,01 
Regression 0.20 6 0.03 4.43 0.001 
OAD/Normalcontrol 0.05 1 0.05 6.03 0.017 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.590 0.604 0.590 
Normal control 0.682 0.669 0.682 
Intertrochanteric Within + residual 0.85 65 0.01 
Regression 0.42 6 0.07 5.41 0.000 
OAD/Normalcontrol 0.13 1 0.13 9.69 0.003 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.840 0.856 0.840 
Normal control 0.978 0.963 0.978 
Ward's triangle Within + residual 0.69 65 0.01 
Regression 0.14 6 0.02 2.22 0.052 
OAD/Normal control 0.08 1 0.08 7.84 0.007 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.382 0.384 0.382 
Normal control 0.474 0.472 0.474 
Obs mean = observed mean ~ ‘ “ 
Adj. mean = adjusted mean 
Est. mean = estimated mean 
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Table 6.3f. Analysis of covariance results for BMDs differences between OAD men and women on 
inhaled steroids and OAD men and women not on inhaled steroids adjusting for body 
height, body weight,cigarette pack year, alcohol intake per week, dietary calcium intake per 
day and load bearing exercise 
BMD Source of variation Sum ofsquare DF MS F S i g o f F 
Total body BMD~~Within + residual oT? ^ o ^ 
Regression 0.09 6 0.01 2.13 0.085 
OAD/Normal control 0.00 1 0.01 0.73 0.402 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
COAD 0.931 0.916 0.931 
Normal control 0.931 0.947 0.931 
Lumbarspine W _ + residual 0.38 30 0.01 
Regression 0.18 6 0.03 2.43 0.049 
COAD/Normal control 0.05 1 0.04 4.27 0.048 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.753 0.733 0.753 
Normal control 0.801 0.821 0.801 
Femoral neck Within + residual 0.16 29 0.01 
Regression 0.12 6 0.02 3.78 0.007 
OAD/Normal control 0.01 1 0.01 1.82 0.188 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
OAD 0.550 0.548 0.550 
Normal control 0.585 0.586 0.585 
Intertrochanteric Within + residual 0.29 29 0.01 
Regression 0.40 6 0.07 6.70 0.000 
OAD/Normal control 0.01 1 0.01 0.67 0.419 
Adjusted and estimated means 
〇bs. mean Adj. mean Est. mean 
OAD 0.786 0.775 0.786 
Normal control 0.794 0.806 0.794 
Ward's triangle Within + residual 0.22 29 0.01 
Regression 0.06 6 0.01 1.22 0 355 
OAD/Normal control 0.01 1 0.01 o.70 0.411 
Adjusted and estimated means 
Obs. mean Adj. mean Est. mean 
〇AD 0.356 0.358 0.356 
Normal control 0.386 0.385 0.386 
Obs mean = observed mean ~ ‘ “ 
Adj. mean = adjusted mean 
Est. mean = estimated mean 
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Table 6.4a. Multiple regression of total body BMD against various variables 
in all OAD patients on inhaled steroids 
Independent variable B SE B~~~ p-value 
Age (year) -4.6e"°' 2.3e'^' 0.11 
Sex (male/female) -1.1e'°^ 8.6e"°^ 0.24 
Duration of Asthma (year) -7.8e° 2.2e'°^ 0.73 
BMI (kg/M') -1.5e_o3 9.9e"^' 0.89 
Daily dietary calcium intake (mg) 1.2e'°^ 3.6e'°^ 0.75 
Cumulative dose of oral steroids (mg) -7.2e'°® 6.1 e"°^  0.99 
Cumulative dose of inhaled steroids (mg) -3.3e"°^ 2.8e'°® 0.91 
Current dose of inhaled steroids (pg per -4.5e'°® 1.1 e"°^  0.97 
day) 
Length of inhaled steroids use (week) 8.9e'°^ 4.4e'°^ 0.85 
Constant i .4 
R2 =0.52, p=0.80 
70 
Table 6.4b Multiple regression of lumbar spine(L1-L4) BMD against 
various variables in all OAD patients on inhaled steroids 
Independent variable B SE B p-value 
Age (year) -7.3e'°^ 1.8e"°^ 0.00 
Sex (male/female) -1.4e"°^ 6.5e'°^ 0.05 
Duration of Asthma (year) -1.4e'°^ 1.6e'°^ 0.39 
BMI (kg/M') 8.4e_o3 7.6e'^' 0.27 
Daily dietary calcium intake (mg) 6.6e"°^ 2.7e"°^ 0.81 
Cumulative dose of oral steroids (mg) -6.9e'°^ 4.7e'°^ 0.16 
Cumulative dose of inhaled steroids (mg) -2.7e"°^ 2.1e'°® 0.90 
Current dose of inhaled steroids {\jg per 3.4e"°^ 8.0e"°^ 0.68 
day) 




Table 6.4c. Multiple regression of femoral neck BMD against various 
variables in all OAD patients on inhaled steroids 
Independent variable B SE B p-value 
Age (year) -6.4e-°' ISe" ' 0.00 
Sex (male/female) -7.6e"°^ 4.7e^ 0.13 
Duration of Asthma (year) -i.3e'°^ 1.2e^ 0.30 
BMI(kg/M2) 8.8e-o3 5.5e-' 0.13 
Daily dietary calcium intake (mg) -2.1 e-°^ 2.0e"°^ 0.31 
Cumulative dose of oral steroids (mg) -9.4e-°^ 3.4e'^^ 0.01 
Cumulative dose of inhaled steroids (mg) 7.9e-°^ 1.5e"°^ 0.61 
Current dose of inhaled steroids (pg per 2.2e-°^ 5.8e'^^ 0.71 
day) 
Length of inhaled steroids use (week) 9.9e-°^ 2.4e^ 0.69 
Constant 10 
R2 = 0.74， p = 0.00 
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Table 6.4d. Multiple regression of hip intertrochanteric region BMD against 
various variables in all OAD patients on inhaled steroids 
Independent variable B SE B p-value 
Age (year) -8.0e'°^ 1.9e"°^ 0.00 
Sex (male/female) -1.3e"°^ 7.1e'°^ 0.10 
Duration of Asthma (year) -1.1 e'°^ 1.8e'°^ 0.56 
BMI (kg/M') 1.8e-o2 8.2e"^' 0.04 
Daily dietary calcium intake (mg) -1.6e'°^ 2.9e'°^ o.58 
Cumulative dose of oral steroids (mg) -8.7e'°^ 5.1e'°^ 0.10 
Cumulative dose of inhaled steroids (mg) 1.3e"°® 2.3e"°® 0.58 
Current dose of inhaled steroids (pg per 4.2e"°® 8.7e"°^ 0.96 
day) 





Table 6.4e. Multiple regression of Ward's triangle BMD against various 
variables in all OAD patients on inhaled steroids 
Independent variable 已 SE B p-value 
Age (year) -1.06"°' 1.7e"^' 0.00 
Sex (male/female) -5.9e'^' 6.3e'^' 0.36 
Duration of Asthma (year) _1.7e"°^ ^ .6e'°^ 0.29 
BMI (kg/M2) 7.8e-o3 7.3e"^^ 0.30 
Daily dietary calcium intake (mg) -5.9e'°^ 2.6e'°^ 0.83 
Cumulative dose ofo「al steroids (mg) -7.7e^^ 4.5e'^^ 0.11 
Cumulative dose of inhaled steroids (mg) 1.2e"°® 2.1 e"°® o.56 
Current dose of inhaled steroids (^jg per -1.1e"°^ 7.7e^^ 0.89 
day) 
Length of inhaled steroids use (week) 4.3e"°^ 3.3e'^^ 0 90 
Gonstant 1 〇 
R' = 0.76’ p = 0.00 
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Figure 6.1. Comparsion of BMDs (g /cm^) in 37 premenopausal OAD patients 
on inhaled steroids and 74 age and BMI matched control subjects 
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Figure 6.2. Comparsion of BMDs (g /cm^) in 36 postmenopausal OAD patients 
on inhaled steroids and 72 age and BMI matched control subjects 
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Figure 6.3. Comparsion of BMDs (g /cm^) in 14 postmenopausal 〇AD patients 
not on inhaled steroids and 28 age and BMI matched control subjects 
1 . 4 " | r 1 . 0 n 1 -
Total Body p=0.850 Femoral neck p=0.572 
1.2-
0.8- ~ ~ 
"c 1.0- "g 0 I ~~I~ “ 
^ 0 . 8 - I I I , I ^ 0 . 6 -
1 i F = ^ = | I 丁 I 
0.6- L _ _ , _ _ J ~ ‘ ~ 
0.4-
0.4-
0.2"l 0.2^  • 
Case Control Casa Control 
Mean 0.824 0.827 Mean 0.502 0.522 
SD 0.066 0.062 SD 0.128 0.024 
1.2] r 1.4n . 
Lumbarspine p=0.088 lntertmchanteric^gion p=0.103 
1.0- 1.2 
"p —T— "e 1.0- _ ^ 0 0.8 5 
I r ~ ^ H = ^ i ° - . T -
ffl 0.6- ZEI i I n I I 
——^—— 0.6- 丨 ’ ——L_ . 
" . 0.4- 丄 
0.2^  ； 0.2^  -
Ca" Control 5；；^ C ^ 
M ^ n 0.639 0.683 Mean 0.652 0.702 
SD 0.088 0.084 SD 0.145 0.069 
0.8n 
Ward's triangle p=0.865 
0 . 6 - ~ ~ 
CM 
E u 
0^.4- ^__L_^ 丁 S -




Mean 0.333 0.327 
SD 0.130 0.053 
Box and whiskers 
The box extends from 25^^  percentile to the 75^^  percentile, with a hortizontal line atthe median (50出 
percentile). Whiskers extend down to the smallest value and up to the largest. 
p-values are of paired t-tests, the paired t-tests preformed on the BMD value of OAD patient on inhaled 
steroids to the mean BMD values of two age and BMI mateched normal subjects 
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Figure 6.4. Comparsion of BMDs (g /cm^) in 33 OAD male patients on 
inhaled steroids and 66 age and BMI matched control subjects 
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Figure 6.5. Comparsion of BMDs (g /cm^) in 24 OAD male patients not on 
inhaled steroids and 48 age and BMI matched control subjects 
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Figure 6.6. Comparsion of BMDs (g/cm^) in 24 OAD patients on inhaled 
steroids and 24 OAD patient not on inhaled steroid 
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Chapter 7 Results for phase 11: Fluoride and 
Calcium trial 
7.1. Factors affects the power of studies 
The statistically power was reduced by the small sample size, the 
minimum required patients of 20 for each of the Tridin or the calcium groups 
in the permuted blocks of A, B and C were not met(Table 5.1). Thirty-seven, 
36, and 33 OAD patients on inhaled steroid were recruited for blocks A, B 
and C, respectively. In addition, the power was further reduced as the OAD 
patients taking Tridin or calcium from each block were matched according to 
sex, age and BMI to minimum their confounding effects. These 
corresponding to 13, 13 and 15 OAD pairs of patients for each of the blocks 
A, B and C, respectively( Chart 7.1). Furthermore, only 8, 8 and 12 OAD 
pairs of patients completed the nine months clinical trial. The power of the 
study was further reduced to less than 0.5. 
Effect of sample size on statistical power with statistical difference of 
0.8, and type 1 error of 0.05 between the Tridin group and the calcium 
Block 
A: Premenopausal B: Postmenopausal C: Men aged over 45 
n dr Power n dr Power n d, Power 
~ ~ ^ ^ 07 ^ ^ 07 ^ 0 8 07~~ 
13 0.8 0.5 13 0.8 0.5 15 0.8 〜0.6 
8 0.8 <0.5 8 0.8 <0.5 12 0.8 0.5 
n: Sample size per group 
dr = Magnitude of difference to be detected between the groups 
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7.2. Clinical findings 
Forty-one pairs of OAD men and women on inhaled steroids matched 
with age, sex, menopausal status(for female) and BMI were included for the 
trial. They were stratified into: Group 1, consisted of all 41 matched pairs of 
OAD patients, group II consisted of 15 pairs of men patients; group III, 
consisted of 26 pairs of women patients; group IV, consisted of 13 pairs of 
pre-menopausal women and group V consisted of 13 pair post-menopausal 
patients (Chart 7.1.) 
Chart 7.1 Stratification for the Tridin or the calcium group 
41 pairs (men orwomen on inhaled steroids) 
G「oup I 
/ \ 
15 pairs(Block C) 26 pairs (women) 
men Group II. 
Group II / \ 
12 pairs completed Z \ 
13 pairs(Block A) 13 pairs(Block B) 
pre-menopause post-menopause 
Group IV Group V 
8 pairs completed 8 pairs completed 
The demographic and lifestyle factors of the age, sex and BMI match-
paired patients at baseline were presented in tables 7.1a to 7.1e. There 
were no statistically significant differences in the above factors between the 
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match-paired patients by paired t-test. Both cumulative doses of oral, and 
inhaled steroids and loading bearing exercise were similar among ali the 
paired groups. Also, other baseline characteristics such as daily dietary 
calcium intake, alcohol consumption and cigarette smoking habits were 
similar(Table 7.1 a.). 
Sixty two patients completed the nine months clinical trial. Of these, 
thirty pairs of age sex and BMI matched pairs were included in the analysis. 
Two patients of the calcium group had to be exclgded from for the analysis 
since their Tridin matched counterparts discontinued the trial. Of the 30 age, 
sex and BMI matched pairs, 12 were OAD men, 9 were OAD pre-
menopausal women and 9 were OAD post-menopausal women. 
Of the 20 patients discontinued the trial: 11 from the fluoride group 
and 9 from the calcium group. The reasons for discontinuing the trial were 
intolerable side effects in 6, personal reasons in 6, deaths not related to the 
trial in 3，being uncooperative in 4 and loss to follow up in 1(Table 7.5a). 
Thirty subjects completed the trial in the Tridin group (Drug intake 
compliance: 59 土 24 %) whilst 32 patients completed the calcium trial (Drug 
intake compliance: 67 土 24 %). There was no statistically significant 
difference in completeness of treatment between the two groups. 
The Tridin treated group experienced about 1.9 times of the side 
effects as many as the group given calcium. The side effects fell into one of 
the two major categories, those due to gastric irritation and those due to pain 
in the lower extremities or both(table 7.5.b). 
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The gastric symptoms consisted mainly of nausea, or less commonly, 
epigastric pain and vomiting， or both. The Tridin treated group had the 
symptom 1.4 times as many as the patients taken calcium(table 7.5.b). 
Lower extremity pain developed relatively acute associated with the 
start of treatment. The patients given Tridin had 1.8 times more episodes 
than those of the patients given calcium. The symptoms usually disappeared 
a few weeks after the treatments were stopped. Only three patients of the 
calcium group experienced muscle pain. Nineteen had no complaint about 
the side effect in the group given Tridin compared to 25 in the group given 
calcium(table 7.5b). 
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7.3. Body measurements and bone mineral densitometry 
The means and SDs of the baseline bone densities for the forty-one 
age, sex, and BMI matched pairs patients were presented in tables 7.2a. 
There were statistically significant differences in percentage of body fat, lean 
body mass, and lumbar spine BMD between the fluoride and the calcium 
groups. However, with stratification based on sex, and menopausal status, 
the percentage of fat and lean body mass were no longer statistically 
significant(Table 7.2b-e). A scatter plot on the baseline lumbar spine BMD 
showed one person assigned to the calcium group had lower BMD(Figure 
7.6). By stratification, it was revealed such patient belonged to the OAD 
female group(Table 7.2.c). 
The means and SDs of the baseline characteristics for the thirty age, 
sex, and BMI matched pairs of OAD patients on inhaled steroids who have 
completed the Tridin or calcium treatments were presented in tables 7.3a to 
7.3e. There were no statistically significant differences in any of the 
parameters listed. 
The individual changes in BMDs at the lumbar spine and hip for each 
treatment groups were shown in figures 7.1 to 7.5. There was a wide scatter 
of percentage changes for the hip BMD(Figure 7.1). Subjects with extreme 
changes were not excluded from the analysis. The percentage changes in 
bone densities of the hip and spine were presented in table 7.4.a to 7.4.e. 
The BMDs of the hip and lumbar spine decreased in both groups of patients 
taking Tridin or calcium. However, the differences in these BMDs were not 
statistically significant by paired t-test. 
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The mean decrease in BMD of the lumbar spine was -11 土 9 % in the 
Tridin group as compared to -9 士 9 % in the calcium group(p value was not 
significant). The corresponding decrease in the bone mineral density of the 
femoral neck were -13 土 9 % in the Tridin group as compared to -11 土 9 % 
in the calcium group(p value not significant); for the intertrochanteric region -
13 土 8 % for the Tridin group and 12 土 10 Q/o for the calcium control; and for 
the Ward's triangle, -14 土 11 % for the Tridin group compared to -10 土 10 
% for the calcium group(Table 7.4.a, and Figure 7.1a). Results for other 
groups were presented in table 7.4b to e, and figure 7.1 to 7.5. 
Patients given Tridin or calcium showed bone losses in all the sites 
studied. The Tridin group showed a bigger fall in bone m ine r3 l densities than 
the group given calcium, but there were no significant differences between 
the two groups. The only site showing significant difference between the two 
groups was the Ward's triangle of the male OAD patients(Group II, p<0.05) 
(Table, 7,4b’ Figure 7.3). Few patients taking either Tridin or calcium 
treatment showed increases in BMDs(Table 7.7). 
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Table 7.1a: Baseline characteristics of all the OAD patients on inhaled steroids at 
start of the clinical trial (mean 土 SD) 
Tridin Calcium 
n= 41 41 
Age (year) 54 土 17 55 土 15 
Age of menarche among female (year) 10 土 8 9 土 1 
Age of menopause among female (year) 48 土 5 50 土 6 
Oral steroid user (%) 
Never 73 73 
ever 27 27 
Cumulativedoseoforalsteroids(mg) 1295 土 1237 411 土 12 
Duration of use of inhaled steroids 40 土 13 45 士 13 
(weeks) 
Cumulativedoseof inhaledsteroids(mg) 389 土 200 416 土 160 
Daily dietary calcium (mg) 213 土 95 214 ±112 
/Mcohol drinking (%) 
never 93 76卞卞 
ever 7 24 
Yearsofd「inkingamongalcohold「inker 15 土 6 27 士 16 
Alcoholintakeamongdrinker(g/week) 182 土 160 139 土 136 
Cigarette smoking(%) 
never 54 68 
ever 46 32 
Years of smoking among cigarette smoker 31 土 13 31 土 12 
Cigarettepackyearamongsmoker 25 土21 39 ± 2 5 
Loading bearing exercise (hour/week) 0.1 土 0 0.1 土 0 
Ever use o「al contraceptives (OC) among 
women(%) 
yes 65 73 
no 35 27 
Months of 〇C use among women 〇C 46 土 71 12 士 14 
user 
Paired T-test: Chi-square test 
•* P < 0.01 tt p<o .o i 
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Table 7.1b: Baseline characteristics of all OAD male patients on inhaled steroids at 
start of the clinical trial (mean 土 SD) 
Tridin Calcium 
n= 15 15 
Age 63 土 9 64 土 9 
〇「al steroid user (%) 
Never 47 Qjm 
Ever 53 13 
Cumulative dose of oral steroids (mg) 1295 土 1237 411 ± 1 2 
Duration of inhaled steroid (week) 36 土 9 42 土 11 
Cumulative dose inhaled steroids (mg) 57 土 23 53 土 23 
Daily dietary calcium (mg) 397 土 160 373 土 159 
Alcohol dhnking(%) 
never 8 0 4 7 t t t 
ever 20 53 
Yearsofdrinkingamongalcoholdrinker 15 ± 6 27 ± 1 3 
Alcohol intake among alcohol drinker 182 土 160 125 土 120 
(g/week) 
Cigarette smoking(%) 
never 20 20 
ever 80 80 
Years of smoking among cigarette 33 土 11 32 土 12 
smoker 
Cigarette pack year among smoker 29 土 17 42 土 25 




Table 7.1c: Baseline characteristics of all OAD female patients on inhaled steroids 
at start of the clinical trial (mean 土 SD) 
Tridin Calcium 
_n= — 26 26 
Age 49 土 18 49 ±16 
Ageofmenarche 14 土 2 15 土 3 
Age of menopause 48 土 5 50 土 6 
Oral steroid user (%) 
Never 89 65卞" 
ever 11 35 
Gumulativedoseoforalsteroids(mg) 0 ± 0 0 土0 
Duration of use of inhaled steroids (week) 43 土 15 47 土 14 
Cumulative dose of inhaled steroids (mg) 384 土 223 441 土 158 
Daily dietary calcium (mg) 216 土 95 229 土 114 
Alcohol d「inking(。/o) 
never 100 92 
ever 0 8 
Years of drinking among alcohol drinker 0 土 0 26 土 34 
Alcohol intake among alcohol drinker 0 土 0 195 土 239 
(g/week) 
Cigarette smoking(%) 
never 7 3 g g i t t 
ever 27 4 
Yearsofsmokingannongcigarettesmoker 27 土 17 20 土 0 
Cigarette pack year among smoker 18 土 26 10 土 0 
Loading bearing exercise (hour/week) 0.0 土 .0 0.1 土 1 
Ever use oral contraceptives (OC) (%) 
Never 65 73 
Ever 35 27 




Table 7.1d Basel ine characterist ics of OAD premenopausal female pat ients on 
inhaled steroids at start of the clinical trial (mean 土 SD) 
Tridin Calcium 
n= 13 13 
Age 33 土 7 35 土 8* 
Ageofmenarcheamongfemale 14 ± 2 14 ± 2 
Oral steroid user (%) 
Never 92 62卞" 
ever 8 38 
Gumulativedoseoforalste「oids(mg) 0 ± 0 0 ± 0 
Duration of use of inhaled steroids 41 土 18 49 土 16 
(weeks) 
Cumulative dose of inhaled steroids (mg) 321 ± 234 460 ± 1 8 9 
Daily dietary calcium (mg) 241 士 77 211 土93 
Alcohol drinking(%) 
never 100 100 
ever o 0 
Yearsofdrinkingamongalcoholdrinker 0 ± 0 0 ± 0 
Alcohol intake among alcohol drinker 0 士 0 0 土 0 
Cigarette smoking(。/。） 
never 92 100 
ever 8 0 
Years of smoking among cigarette smoker 4 土 0 〇 土 〇 
Cigarette pack yea「among smoker 1 土 〇 0 土 0 
Loadingbearingexercise(hour/week) 0.0± 〇 0.1± 0 
Ever use oral contraceptives (OC)(%) 
never 39 54^ 
ever 61 46 
MonthsofOCuseamongOCuser 23 土 18 12 土 15 
Pair*ed t-test: Chi-square test: 
* P < 0.05 卞 p<0.05 
卞竹 p<0.001 
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Table 7.1e Baseline characteristics of OAD postmenopausal female patients on 
inhaled steroids at start of the clinical trial (mean 土 SD) 
Tridin Calcium 
^ 13 
Age 66 土 1 63 土 6 
Ageofmenarche 15 土 2 17 土 3* 
Age of menopause 48 土 5 50 土 6 
Oral steroid user (%) 
Never 85 69 
ever 15 31 
Cumulative dose of oral steroids (mg) 0 ± 0 0 ± 0 
Duration of use of inhaled steroids (week) 45 土 13 45 土 13 
Cumulative dose of inhaled steroids (mg) 447 士 201 423 土 124 
Daily dietary calcium (mg) 191 土 107 247 土 133 
Alcohol drinking(%) 
never 1 0 0 86付卞 
ever 0 14 
Years of drinking among alcohol drinker 0 土 0 26 土 34 
Alcohol intake among alcohol drinker 〇 土 0 195 士 239 
(g/week) 
Cigarette smoking(%) 
never 54 92卞打 
ever 46 8 
Years of smoking among smoker 31 土 14 20 土 0 
Cigarette pack year among cigarette smoker 21 土 27 10 土 0 
Loading bearing exercise (hour/week) 0 土 0 0.2 土 1 
Ever use oral contraceptives(OC) among 
female(%) 
never 92 92 
ever 8 8 
Months of 〇C use among 〇C user 228 土 0 12 土 0 
Paired t-test: Chi-square test 
* P<0.05 ttt p<0.001 
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Table 7.2e: Baseline body measurement and bone mineral density of OAD post-
menopausal female patients on inhaled steroids at baseline(mean 土 SD) 
Treatment 
Tridin Calcium 
Qf ^ ^ j 
Body measurement 
Weight (kg) 58 士 8 55 ±14 
Height {m) 1.6 土 0 1.5 ±0 
BMI {kg/H') 24 土 3 24 土 4 
Fat mass (kg) 20 土 8 17 土 15 
% of body fat (kg) 36 土 9 28 土 18* 
Lean body mass (kg) 36 土 7 30 土 18 
Bone mineral density (gm/cm^) 
Spine (L1-L4) 0.825 士 0.181 0.654 土 0.353** 
Femoral neck 0.665 土 0.143 0.668 土 0.138 
Intertrochanteric 0.904 土 0.198 0.928 土 0.169 
Ward's triangle 0.519± 0.199 0.523 土 0.192 
Paired t-test 
* p < 0.05 
** p < 0.01 
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Table 7.2b Baseline body measurement and bone mineral density of OAD male 
patients on inhaled steroids at baseline(mean 土 SD) 
Treatment 
Tridin Calcium 
n= ^5 ^5 
Body measurement 
Weight (kg) 59 土 1 57 土 11 
Height (m) 1.6 土 0 1.6 土 0 
BMI (kg/H') 23 土 3 22 土 3 
Fat mass (kg) 14 土 5 9 士 12 
% of body fat (kg) 26 土 5 19 土 14 
Lean body mass (kg) 41 土 8 31 土 25 
Bone mineral density (gm/cm^) 
Spine (L1-L4) 0.832 土 0.157 0.726 土 0.315 
Femoral neck 0.644 土 0.108 0.652 土 0.102 
Intertrochanteric 0.903 土 0.162 0.894 土 0.154 
Ward's triangle 0.466 士 0.112 0.458 土 0.118 
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Table 7.2e: Baseline body measurement and bone mineral density of OAD post-
menopausal female patients on inhaled steroids at baseline(mean 土 SD) 
Treatment 
Tridin Calcium 
Qf_ ^ ^ 
Body measurement 
Weight (kg) 57 土 9 54 土 16 
Height (m) 1.5 土 0 1.4 土 0 
BMI (kg/H') 25 土 3 25 土 5 
Fat mass (kg) 24 土 6 24 土 15 
% of body fat (kg) 41 士 6 32 土 19 
Leanbodymass(kg) 34 土 4 29 土 14 
Bone mineral density (gm/cm^) 
Spine (L1 -L4) 0.822 土 0.196 0.613 土 0.373* 
Femoral neck 0.673 土 0.164 0.683 土 0.153 
Intertrochanteric 0.909 土 0.222 0.943 土 0.174 






Table 7.2e: Baseline body measurement and bone mineral density of OAD post-
menopausal female patients on inhaled steroids at basel ine(mean 土 SD) 
Treatment 
Tridin Calcium 
n= 23 ^_3 
Body measurement 
Weight (kg) 58 土 9 53 土 19 
Height (m) 1.6 土 0 1.4 土 0 
BMI (kg/H') 24 土 3 24 土 4 
Fat mass (kg) 23 土 6 24 士 13 
% of body fat (kg) 38 土 5 34 土 13 
Lean body mass (kg) 35 土 3 34 土 5 
Bone mineral density (gm/cm^) 
Spine (L1-L4) 0.954 土 0.127 0.701 土 0.413 
Femoral neck 0.791 土 0.047 0.800 土 0.106 
Intertrochanteric 1.062 土 0.101 1.069 土 0.148 
Ward's triangle 0.728 士 0.099 0.746 土 0.138 
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Table 7.2e: Baseline body measurement and bone mineral density of OAD post-
menopausal female patients on inhaled steroids at basel ine(mean 土 SD) 
Treatment 
Tridin Calcium 
n= ^3 ^_3 ^ 
Body measurement 
Weight (kg) 56 土 9 54 士 12 
Height {m) 1.5 土 0 1.4 土 0 
BMI (kg/H') 25 土 4 25 土 5 
Fat mass (kg) 25 土 7 18 土 17 
% of body fat (kg) 43 ± 7 31 ± 2 4 
Leanbodymass(kg) 32 土 3 24 土 18 
Bone mineral density (gm/cm^) 
Spine (L1-L4) 0.689 土 0.161 0.525 土 0.319 
Femoral neck 0.574 土 0.144 0.546 土 0.098 
Intertrochanteric 0.824 土 0.150 0.750 土 0.161 
Ward's triangle 0.385 士 0.167 0.364 土 0.098 
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Table 7.3 a: Baseline characteristics of the 30 pairs of OAD patients on inhaled 
Jgroids who have completed the Tridin and calcium clinical trial (mean 土 
O U j 
一 Tridin Calcium 
n= 30 30 
Age(year) 5 5 ± 1 6 乂土 1 4 
Age of menarche among female (year) 14 土 2 15 土 3 
Ageofmen〇pauseamongfemale(yea「) 47 土 5 51 土 g 
Oral steroid user (%) 一 
Never 73 73 
ever 27 27 
Cumu la t i ve dose of ora l s te ro ids (mg) 168 ± 328 146 ± 2 9 2 
Duration of use of inhaled steroids (weeks) 40 土 14 44 土 ^  ^  
Cumu la t i ve dose of i nha led s tero ids (mg) 394 土 ^ 9 5 3 8 i + ^ 2 0 
Daily dietary calcium (mg) 216 士 94 196 ± 81 
Alcohol drinking (%) 一 
隱 「 90 67 
eve「 10 33 
Years of drinking among alcohol drinker 15 土 6 27 土 16 
Alcohol intake among drinker (g/week) 91 土 37 59 土 gg 
Cigarette smoking(%) 
never 47 70 
ever 56 30 
Years of smoking among cigarette smoker 35 土 8 34 土 ^  ^  
Cigarette pack year among smoker 35 土 ^g 47 + 21 
Loading bearing exercise (hour/week) 0 土 0 0 + 0 
Ever use oral contraceptives (OC) among 
w o m e n ( % ) 23 py 
never 67 73 
ever ‘ 。 
Months of 〇C use among women 〇C user 1 土 〇 1 + 〇 
Body measurement and bone mineral density 
(gm/cm) 
^^ '9h t (kg) 5 8 ± 8 57 . 11 
Height(m) 1.5 土 o 1 5 : 1 
_ (kg/H2) 24 ± 3 24 ： 4 
Fatmass(kg) 21 土 6 20 土 9 
%ofbodyfat(kg) 36 土 8 34 土 11 
Lean body mass (kg) 37 士 6 36 土 8 
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Table 7.3 b: Baseline characteristics of the 12 pairs of OAD men on inhaled steroids 
who have completed the Tridin and calcium clinical trial (mean 土 SD) 
Tridin Calcium 
门 = 1 2 1 2 
Age (year) 62 土 9 63 土 8 
Oral steroid user (%) 
Never 50 92 
ever 50 8 
Cumulative dose of oral steroids (mg) 239 土 287 34 土 116* 
Duration of use of inhaled steroids (weeks) 35 土 9 40 土 12 
Cumulative dose of inhaled steroids (mg) 354 土 143 303 土 72 
Daily dietary calcium (mg) 216 土 83 181 土 109 
Alcohol drinking (%) 
never 75 33 
ever 25 67 
Yearsofd「inkingamongalcohold「inker 19 土 1 30 土 14 
Alcohol intake among drinker (g/week) 91 土 37 59 土 46 
Cigarette smoking(%) 
never ^ j 25 
ever 83 75 
Years of smoking among cigarette smoker 35 土 8 34 土 11 
Cigarette pack year among smoker 36 土 19 47 土 21 
Loading bearing exercise (hour/week) 0 土 0 0 土 0 
Body measurement and bone mineral density (gm/cm^) 
Weight (kg) 56 土 7 59 土 11 
Height (m) 1 . 6 ± 0 1 . 6 ± 0 
BMI (kg/H') 23 土 3 22 土 3 
Fat mass (kg) 16 土 2 15 土 5 
o/o of body fat (kg) 27 土 3 26 土 4 





Table 7.3 c: Baseline characteristics of the 18 pairs ofwomen OAD patients on inhaled 
steroids who have completed the clinical trial (mean 土 SD) 
Tridin Calcium 
n= 18 18 
Age (year) 50 土 18 48 土 15 
Age of menarche among female (year) 14 土 2 15 土 3 
Age of menopause among female (year) 47 土 5 51 土 1 
Oral steroid user (%) 
Never 89 11 
ever 11 7 
Cumulativedoseoforalsteroids(mg) 121 土 353 222 土 349 
Durationofuseofinhaledsteroids(weeks) 43 土 17 46 土 10 
Cumulative dose of inhaled steroids (mg) 422 土 224 432 土 119 
Daily dietary calcium (mg) 216 土 103 206 土 56 
Alcohol drinking (%) 
never 100 89 
ever 0 11 
Years of drinking among alcohol drinker 0 土 0 26 土 34 
Alcoholintakeamongd「inke「(gAA/eek) 0 土 0 195 土 239 
Cigarette smoking(%) 
never 67 100卞 
ever 33 0 
Years of smoking among cigarette smoker 0 土 0 0 土 0 
Cigarette pack year among smoker 8 土 8 0 土 0 
Loading bearing exercise (hour/week) 0 土 0 0 土 0 
Ever use oral contraceptives (OC) among 
women(%) 67 72 
yes 33 28 
门 0 
Months of 〇C use among women 〇C user 1 土 0 1 土 0 
Body measurement and bone mineral density (gm/cm^) 
Weight (kg) 57 土 9 55 土 10 
Height (m) 1.5±0 1.5±0 
BMI (kg/H2) 25 ± 4 25 土 5 
Fat mass (kg) 23 土 6 22 土 9 
% of body fat (kg) 41 土 6 39 土 10 





Table 7.3 d: Baseline characteristics of the 9 pairs of pre-menopausa! women 〇AD 
patients on inhaled steroids who have completed the clinical trial (mean 土 
SD) 
Tridin Calcium 
n= 9 9 
Age (year) 34 土 6 36.8±9.4* 
Ageofmenarcheamongfemale(year) 14 土 2 13.0±1.4 
Oral steroid user (%) 
Never 100 44卞 
ever 0 46 
Cumulative dose of oral steroids (mg) 0 土 0 350土432.9 
Duration of use of inhaled steroids (weeks) 40 土 19 44士11.4 
Cumulative dose of inhaled steroids (mg) 322 土 212 408±125.1 
Daily dietary calcium (mg) 231 ±11 214±69.5 
Alcohol drinking (%) 
never 89 100 
ever 11 0 
Yearsofd「inkingamongalcohold「inker 0 土 0 0 土 0 
Alcohol intake among drinker (g/week) 0 土 0 0 土 0 
Cigarette smoking(%) 
never 89 100 
ever 11 o 
Years of smoking among cigarette smoker 0 土 0 0 土 0 
Cigarette pack year among smoker 0 土 0 0 土 0 
Loading bearing exercise (hour/week) 0 土 0 0 土 0 
Ever use oral contraceptives (OC) among 
women(%) 67 33 
never 33 67 
ever 
Months of OC use among women OC user 0 土 0 0 土 0 
Body measurement and bone mineral density (gm/cm^) 
Weight (kg) 56 土 10 55 土 8 
Height (m) 1 . 5 ± 0 1 . 5 ± 0 
BMI (kg/H2) 24 ± 3 24 土 4 
Fat mass (kg) 22 土 6 20 土 7 
o/o of body fat (kg) 38 土 5 38 土 8 
Lean body mass (kg) 35 土 4 32 土 4 
Paired t-test: Chi-square test 
* P < 0.05 卞 p < 0.05 
1 0 0 
Table 7.3 e Baseline characteristics of the 9 pairs of post-menopausa! women OAD 
I patients on inhaled steroids who have completed the clinical trial (mean 土 
I SD) 
i ^ 
i Tridin Calcium 
j n= 9 9 
Age (year) 67 土 1 60 土 9* 
Age of menarche among female (year) 15 土 2 17 土 3 
Age of menopause among female (year) 47 土 5 515 士 1 
Oral steroid user {%) 
Never 78 78 
I ever 22 22 
[ Cumulativedoseoforalsteroids(mg) 241 土 481 93 土 185 
I Duration of use of inhaled steroids (weeks) 47 土 14 48 土 10 
I Cumulativedoseofinhaledsteroids(mg) 521 土 198 456 土 114 
j Daily dietary calcium (mg) 201 土 126 198 土 40 
丨 Alcohol drinking (%) 
i never 100 78 
\ ever 0 22 
I Yearsofdrinkingamongalcoholdrinker 0 土 0 0 土 0 
j Alcohol intake among drinker (g/week) 0 土 0 0 土 0 
,’ Cigarette smoking(。/。） 
‘ never 44 100卞 
I ever 56 0 
I Years of smoking among cigarette smoker 0 土 0 0 土 0 
I Cigarette pack year among smoker 0 土 0 0 土 0 
/ 
I Loading bearing exercise (hour/week) 0 土 0 0 土 0 
I Ever use oral contraceptives (OC) among 
I women(%) 100 78 
t yes 0 22 
i no 
I Months of OC use among women 〇C user 0 土 0 0 土 0 
i 
I 
£ Body measurement and bone mineral density (gm/cm^) 
I Weight (kg) 57 土 9 56 土 12 
I Height (m) 1.5 土 0 1.5 土 0 
；： BMI (kg/H') 26土 4 25 ± 5 . 1 
I Fat mass (kg) 25 土 6 24 土 11 
® % of body fat (kg) 43 土 6 40 土 13 




i Paired t-test: Chi-square test 
聚 * P<0.05 卞 p<0.05 
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 7.5.a. FReasons for withdrawn f「om the Tridin and calcium clinical trial in the 
20 OAD patients on inhaled steroids 
Symptom / Number of patient No. of patients No. of episodes 
Tridin Calcium Tridin Calcium 
Gl discomfort 4 1 8 3 
(Gastric pain, nausea, vomiting) 
Muscle pain 0 1 0 2 
Died 1 2 NA NA 
No complaints 4 2 NA NA 
Others 
Lost to follow up 1 0 
Uncooperative 1 3 
Total number of withdrawn 11 9 
Number of patients completed the trial 30# 32 
Total number of patients 41 41 
Note: # Analysis were carried out based on these 30 pairs of patients, 2 patients from the calcium group was not 
used in the analysis since their corresponding Tridin niatch withdrawn from the trial 
1 0 7 
Table 7.5.b. Symptoms and side-effects from the Tridin and calcium clinical trial in 
the OAD patients on inhaled steroids 
Symptom No. of patients No. of episodes 
Tridin Calcium Tridin Calcium 
Gl discomfort(%) 
(Gastric pain, nausea, vomiting) 13(32) 6(15) 25(76) 14(58) 
Lower back pain(%) 6(15) 2(5) 8(24) 5(21) 
Muscle pain(%) 0(0) 3(7) 0() 5(21) 
• r s ( % ) 2(5) 3(7) NA NA 
Died 1(2) 2(5) NA NA 
No complaints(%) 19(46) 25(61) NA NA 
她 丨 “ 4 1 ( 1 0 0 ) ~ 4 1 ( 1 0 0 ) 3 3 ( 1 0 0 ) ~ " 2 4 ( 1 0 0 ) 
1 0 8 
i 
Table 7.6 Number of patients showing increase in BMD after treatment 
Group 丨 Group II Group 丨丨丨 Group IV Group V 
All patients Male Female Pre- Post-
menopausal menopaus 
al 
Number of (n=30) (n=12) (n=18) (n=9) (n=9) 
patients(%) 
Lumbar spine(L1-L4) “ ‘ 
Fluoride 3(10) 1(8) 2(11) 2(22) 0(0) 
Calcium 8(27) 4(33) 4(22) 1(11) 3(33) 
Femoral neck 
Fluoride 2(7) 1(8) 1(6) 1(11) 0(0) 
Calcium 3(10) 2(17) 1(6) 0(0) 1(11) 
Intertrochanteric region 
Fluoride 2(7) 0(0) 2(11) 1(11) 1(11) 
Calcium 1(3) 1(8) 0(0) 0(0) 0(0) 
Ward's triangle 
Fluoride 2(7) 0(0) 2(11) 0(0) 2(22) 
Calcium 5(17) 4(33) 1(6) 0(0) 1(”） 
• 




Table 7 7 Gompliance of Tridin or calcium intake for OAD patients on inhaled 
steroid completed the nine months clinical trial 
Tridin Calcium 
Group Mean 士 SD(range) Mean 土 SD(range) 
1:AII patients(30) 59 土 24(16-100) 67 土 24 (16-97) 
2:Male patients(12) 56± 25 (16-100) 63 土 24 (21-97) 
3:Female patients(18) 63 土 24(20-94) 74 土 24 (16-96) 
4:Premenopausal female(9) 56 土 27(16-99) 60 土 22 (28-93) 
5:Postmenopausal female(9) 56 土 24 (29-100) 65 土 27 (21-97) 
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Figure 7.3. Effects of Tridin and Calcium supplementation on percentage 
changes on BMDs in 18 age and sex matched-pair of OAD 
female Chinese patients 
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Figure 7.4. Effects of Tridin and Calcium supplementation on percentage 
change on BMDs in 9 age and sex matched-pair of OAD 
pre-menopasual female Chinese patients 
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Figure 7.3. Effects of Tridin and Calcium supplementation on percentage 
changes on BMDs in 18 age and sex matched-pair of OAD 
female Chinese patients 
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Figure 7.4. Effects of Tridin and Calcium supplementation on percentage 
change on BMDs in 9 age and sex matched-pair of OAD 
pre-menopasual female Chinese patients 
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Figure 7.4. Effects of Tridin and Calcium supplementation on percentage 
change on BMDs in 9 age and sex matched-pair of OAD 
pre-menopasual female Chinese patients 
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Figure 7.6. Baseline lumbar spine (L1-L4) BMD in 41 age and sex matched-pair 
of OAD Chinese patients 0门 Tridin or calcium treatment 
1.2n 
〇 
1.1- 00 S 
〇 
〇〇 〇 
1.0- 〇o 〇o 
o§〇 o 
〇〇o o o。。 
0.9- 〇〇〇 〇 
o ^ 
〇〇 〇〇 
0 . 8 - o g o 0 〇 0 〇 0 
^ . 〇〇 Qo 
E o 〇 o ^ 
i£ o〇〇 〇〇〇 ^07- 〇〇〇 o O 
Q u.z 〇 〇 
i ^ o 8 〇o〇 
• 〇 〇 
0.6- 8 ^ 8 
0.5- 0 
〇 





Tridin Calc ium 
1 1 6 
•1 
Chapter 8: Discussion for phase I 
Inhaled steroids are clearly effective in improving the control of 
asthma and lung functions among OAD patients. They are considered as 3n 
established and safe mode of therapy(Tarlo, S. M., Broder, I. et al, 1988). It 
is generally believe that the impact of inhaled steroids on BMD is 
significantly less than that of therapeutically equivalent doses of oral 
steroids. Recently, the possible long term side effects of inhaled steroids 
therapy on b〇ne densities of asthmatic or OAD patients have been studied, 
but no clear "dose and time threshold" have been established(Bames, N. C., 
1993). 
Long-term systemic steroid therapy in OAD patients is associated with j 
i 
decreased trabecular bone density, and osteoporosis has been found to ^ 
I 
occur in 10-40% of OAD patients(Ruegsegger, P., Medici, T. C. et al, 1983; 
I 
William, S. J.. 1988). ！ 
Examination of biochemical indices suggests that inhaled 
corticosteroids may diminish bone formation as evidenced by a decrease in 
serum osteocalcin level(Teelucksingh, S., Padfield, P. L, et al, 1991), and 
an increase in bone resorption as shown by increased hydroxyproline output 
in urine(Ali, N. J.. Capewell, S. et al, 1991). Conflicting results are reported 
0门 the study of the adverse effect on bone density. Some authors(Reid, D. 
M., Nicoll, J. J. et al, 1986) reported that the use of inhaled steroids in adults 
may also play a role in the development of osteoporosis, although recent 
data did not confirm this possibility(Baraldi, E., Bollini, M. C., et al, 1994). 
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Baraldi showed that therapy with inhaled beclomethasone 
diproprionate(BDP) (300 - 400 pg d a / ” does not cause bone density loss in 
asthmatic children treated over a period of six months. 
Some of the problems associated with the BMD assessment include 
different methods and skeletal sites used, small number of patients included 
in the study, and the use of sub-optimally matched control subjects for 
comparison, ln this study, normal healthy control subjects are carefully 
matched for factors known to potentially affect BMD such as age, sex, and 
BMI(Appendix 3). However, it is practically impossible to find patients with 
similar degree and duration of asthma who have not been treated with some 
steroid medications. 
The BMDs of the total body, lumbar spine, femoral neck, 
intertrochanteric region and Ward's triangle for the OAD premenopausal ; 
i 
women on inhaled steroids, the OAD postmenopausal women on inhaled 
steroids, the OAD postmenopausal women not on inhaled steroids, the OAD 
men on inhaled steroids, and the OAD men not on inhaled steroids were 
analysed separately. The BMDs of the OAD men and women on inhaled 
steroids were compared with the OAD men and women not on inhaled 
steroids. 
The results of this study suggest that therapy with inhaled steroid of 
500 - 4000 \jg day'\ (n = 106) over a treatment period of 14 - 76 weeks did 
not greatly affect bone mineral density in women. Both the premenopausal 
and postmenopausal 〇AD women shown little changes in BMDs at the 
femoral neck(p value not significant), intertrochanteric region(p value not 
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significant) and Ward's triangle(p value not significant), except the lumbar 
spine(p<0.05). These findings were similar to previously reported(Herrala, J., 
Puolijoki, H., et al, 1994) using 1000 pg / day for over 1 year. 
The BMDs of lumbar spine(p<0.01), femoral neck(p<0.05), 
intertrochanteric region(p<0.01) and Ward's triangle(p<0.05) of male OAD 
patients on inhaled steroid were statistically significant lower than those of 
their matched normal controls. However, the disease itself could contribute 
to the loss of BMDs in these patients, since the male OAD patients not on 
steroid inhalers also had lower BMDs at these bone sites compared with 
their age matched normal controls. Furthermore, in these two groups of 
patients, the duration and quality of alcohol intake and cigarette smoking 
are greater. When the BMDs were adjusted for covarience, no statistically 1 
I 
significant differences were found between the OAD men on inhaled steroids 
and their matched normal controls(table 6.3d). However, the BMDs of the 
femoral neck(Sig of F=0.017), intertrochanteric region(Sig of F=0.003) and 
Ward's triangle(Sig of F=0.007) of OAD men not on inhaled steroids were 
statistically significantly lower than those of their matched normal 
controls(table 6.3e). Moreover, only the BMD of the lumbar spine of the older 
OAD men and women on inhaled steroids was statistically significantly lower 
than that of the OAD men and women not on inhaled steroids(table 6.2f, 
table 6.3f.). These results suggest that inhaled steroids dose of 1374 土 445 
M9 for 40 土 11 weeks did not affect BMDs of the total body, lumbar spine, 
femoral neck, intertrochanteric region and Wards' triangle of OAD men. 
1 1 9 
The BMD of lumbar spine was significantly lower in the older OAD 
patients on inhaled steroids(table 6.3f), while the other bone sites were not 
affected by inhaled steroids. 
The total body BMD results from all the OAD men and women groups 
on or not on inhaled steroids suggested that this is not affected by factors of 
using inhaled steroids, ageing, sex, cigarette smoking and alcohol 
consumption. These factors are more important in the loss of BMDs at the 
lumbar spine and the hip. Pre-menopausal women patients were least 
affected by inhaled steroids, and this is followed by the post-menopausal 
women, and the OAD men. 
Factors which affect BMD include age, sex, BMI, fat mass, alcohol 
consumption and cigarette smoking. These factors may confound the 
relationships among OAD, steroid treatment and BMD. 
Inhaled steroids ranging from 600-2000 pg per day for 14 to 64 weeks 
do not affect the total body and hip BMDs in the post-menopausal OAD 
women patients, but inhaled steroids ranging from 800-2250 fjg per day for 
20 to 62 weeks affects the spine and hip BMDs in OAD men patients( p < 
0.05 to p < 0.001). The BMD of lumbar spine of the OAD patients on inhaled 
steroids was significantly lower than that of the OAD patients not 0门 inhaled 
steroids. The BMDs of total body, femoral neck, intertrochanteric region and 
Ward's triangle were lower than those of the OAD patients not on inhaled 
steroids but the differences were not significant. 
These results suggest OAD men with smoking habits are more likely 
to be affected by inhaled steroids on their BMDs. The OAD women were less 
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affected. This might be explained by the fact that the pre-menopausal 
females do not reach peak bone mass until around 40 years of age. In this 
study the average age was of the pre-menopausal women was 36(Table 
6.1), and the normal osteogenesis process might protect them from bone 
loss due to inhaled steroids therapy.丨门 the postmenopausal group, the 
average age was 64 years old, and the mean body fat content was 31 %. 
High body fat may contribute towards higher BMD since the 
androstenedione in fat tissue is the principal source of oestrogen in 
postmenopausal women(Crilly, R. G., Cawood, M., et al, 1988). 
Assessments of total dietary calcium by the frequencies recall method 
has several limitations, such as it is subject to recall bias, and food portion 
size variations. Several items should be added to the list, such as beef, pork 
and chicken, since they are frequently found in Chinese diet. Furthermore, 
food that has been taken frequently by the patient but not mentioned in the 
item list should be taken into account, and the calcium contents in such food 
item can be deduced from the food composition table assembled by the 
Royal Society of Chemistry, London(Royal Society of Chemistry, 1991). 
Our findings differ from one of the previously reported Hong Kong 
study(lp, M., Lam, K., et al, 1994). Ip and her colleagues found a significant 
decrease in BMDs of lumbar spine(L2-L4), femoral neck, trochanter, and 
Ward's triangle in 18 premenopausal women with mean age less than 41.5 
years old using inhaled steroids, beciomethasone or budesonide, in average 
dose of1,100 土 510 \jg / day for 40 士 43.1 months(table 8.1). The difference 
between the two studies among premenopausal female OAD patients from 
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the same region and using similar selection criteria is unexpected. This is 
most likely due to the differences in the duration and cumulative dose of 
inhaled steroids among the patients since duration was longer and the 
dosage was higher among lp，s subjects compared with our patients. In 
addition, they found no statistical difference in the BMDs between men 
patients and their matched controls, in contrast to the finding of this study. 
The differences in the BMD between the men OAD patient and control 
groups of the two studies may be due to the differences in age between the 
two cohorts and in part due to the small sample size in lp and her 
colleagues' study. 
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Table 8.1. Comparisons of demographic data between lp and our 
premenopausal OAD patients on inhaled steroids 
(lp, M. 1994) Our premenopausal 
OAD female patients 
Male:femalerat iono 12:18 37 female 
Age, year 33土10.0 36±7.4 
BMI 21±3.2 25±3.6 
Duration of use of inhaled 40i43.1 10±3.8 
steroid, (month) 
Cumulative dose per 932±1’023 389±179.5 
patient, (mg) 
Average daily dose, (pg) 1,10〇±510 1,310±569.1 
Dietary calcium intake (mg 536 216 
per day) 
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CHAPTER 9: Discussion for phase II: Tridin and 
Calcium trial 
Many previous studies have indicated that elemental fluoride can 
improve bone density. However there were conflicting reports on the type 
and quality of bone in subjects undergoing such treatment. 
1门 this study, attempt has been made to evaluate the effect of 
elemental fluoride as monofluorophosphate on bone mineral density in 0/KD 
patients taking inhaled steroids. Age, sex and BMI matched OAD patients 
were either given monofluorophosphate - calcium tablets(Tridin) or calcium 
tablets without monofluorophosphate for nine months. At the end of the trial 
percentage changes in BMD were compared between the two groups by 
paired t-test. 
Our results indicated that BMD decreased in both the Tridin and 
calcium treatment groups. The group treated by Tridin has a larger decrease 
in BMDs of the lumbar spine and three hip sites than the group given 
calcium only(table 7.4). However, there differences were not statistically 
significant. This was partly due to the small study sample size. 
For the lumbar spine BMD, our「esults from both the Tridin or calcium 
groups were lower than that of Pouilles(Pouilles, J. M., Tremollieres, F., et 
al, 1991). Fo「instance, in our all patients group (group I, table 7.4) showed 
an 8.6% decrease in lumbar spine BMD in the group given calcium after 9 
months of treatment compared with Pouills' study which showed a 2% 
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decrease in lumbar spine BMD in the group given calcium after 6 months of 
treatment(Pouilles, J. M., Tremollieres, F., et al, 1991). 
The findings of the BMDs at the hip sites are similar to many 
previously reported observations(Riggs, B. L., Hodgson, S. F., et al, 1990; 
Pouilles, J. M., Tremollieres, F., Causse, E., et al, 1991; Zerwekh, J. E., 
Hagler, H. K., et al, 1994; Reginster, J. Y.. 1995)(Table 4.5.). The BMDs of 
different hip sites have shown little or no significant changes with fluoride 
treatment with doses of 26.4 to 75 mg pe「day for 6 to 48 months.丨门 our 
study, the decrease in femoral neck BMD in the group given Tridin is five 
folds(Pouilles, J. M., Tremollieres, F., et al, 1991), and eight folds of 
Pouilles’ and Rizzoli, findings respectively(Rizzoli, R., Chevalley, T., et al, 
1995). 
In general, the BMDs of the hip decrease more rapidly than that of the 
lumbar spine(Table 7.4), and similar findings were observed for the group 
given calcium. 
in our study, only 3 patients (10%) in the Tridin group showed 
increases in the lumbar spine BMD, whilst 8 patients (27%) in the calcium 
group showed increases in the lumbar spine BMD(Table 7.7, Figure 7.1). 
Other researchers have shown a 35% increase in lumbar spine BMD after 6 
months of fluoride treatment. Some researchers have suggested that fluoride 
non-responders may have a different genotype resulting in lower oestrogen 
receptor activity(Kobayashi, S., l _ e , S. et al, 1996); and other researchers 
have reported that vitamin D receptor activity may also play a role in the 
regulation of BMD(Houston, L. A., Grant, S. F. A. et al, 1996). Genetic 
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variation in the activities of these receptors may result in the differences in 
response to fluoride. 
Our study period of 9 months is relatively short. Previous studies last 
from 6 months to 6 years(Meunier, P. J., 1990; Riggs, B. L., Hodgson, S. F., 
et al, 1990; Pouilles, J. M., Tremollieres. F., et al, 1991; Riggs, B. L., WM, 0. 
F., et al, 1994; Thiebaud, D.. Burckhardt, P.. et al, 1994; Rizzoli, R., 
Chevalley, T., et al, 1995). However, many of these studies showed change 
in BMD occurring within 6 months of fluoride treatment(Meunier, P. J., 1990; 
Riggs, B. L., Hodgson, S. F., et al, 1990; Pouilles, J. M., Tremollieres, F., 
Causse, E., 1991; Thiebaud, D., Burckhardt, P., et al, 1994; Rizzoli, R., 
Chevalley, T., et al, 1995). Our dosage of 20 mg fluoride is low compared 
with many other reported studies with dosages varied from 26.5 mg to 75 mg 
fluoride per day. 
For our Tridin and its sub-groups, the BMD results were lower than 
that of the calcium alone sub-groups. It is believed that a high dose of (40-
200 mg) fluoride can cause fluorosis, while low fluoride dosage of(20-40 mg) 
may induce bone formation. Fo「example, it has been demonstrated that 
daily intake of 44.2 mg NaF or more can cause osteomalacia. The 
combination dosage of elemental fluoride and calcium(TYidin) in our study 
was based on the data from the Caucasian studies. Thus, the dosage might 
not be appropriate for Chinese patients. 
In summary, some of the previously reported studies suggested that 
high dose of elemental fluoride results in a decrease of BMD while lower 
dose of elemental fluoride results in an increase of BMD. In our study, the 
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mean fluoride intake after adjusted for compliance was 12 mg / day, which is 
relatively lower when compared with other European studies(Riggs, B. L., 
Hodgson, S. F., et al, 1990; Meunier, P. J., 1990; Zerwekh, J. E., Hagler, H. 
K., et al, 1994). However, decreases in BMDs among the patients were 
observed. Possible explanations are that their calcium intake are not 
sufficient and / or the fluoride supplement is not optimum. Either too low or 
too high of fluoride concentration would affect bone formation. Hence serum 
fluoride measurement may be needed in order to confirm its bioavailability 
for bone formation. Many other researchers have shown that fluoride has a 
narrow therapeutic window, and this fluoride therapeutic window may vary 
with age and race. 
Side effects of arthritis, fasciitis, acute lower extremity pain 
syndrome(Riggs, B. L., Hodgson, S. F., et al, 1990; Pouilles, J. M., 
Tremollieres, F., et al, 1991) are all factors that affect the patients， 
willingness to continue the treatment. In part the odour and size of the 
tablets may also reduce their compliances with treatment. 
In addition, the high dropout rate reduced the power from 0.7 to less 
than 0.5. with a postulated statistical difference of 0.8 between the Tridin 
and the calcium groups. The high dropout rate also destroyed the 
permutation blocks, which in term reduced the degree of randomisation. 
Furthermore, scatter age distribution occurred in each block limited the 
randomisation. BMDs were affected by age, sex and BMI, hence， large 
sample size with a power of 0.8 and a lower postulated statistically 
difference was needed. 
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In order to improve the statistical power of the studies more patients 
will be needed and these patients can be recruited from different government 
clinics in hlong Kong. These potential subjects may be reviewed by a 
medical doctor in o「de「to reduce the selection bias. Their medical records 
regarding to the past history of medication may be useful in determining their 
true exposure to inhaled steroids. Unfortunately, most people have had more 
than one general practitioner during their life-time. Hence, it is difficult to 
deduce their usage of different steroids. 
Recall bias may be reduced in asking subject's daily calcium intake, if 
a diary form can be given to the potential subjects and request them to 
record their dietary intake. 
A placebo group is needed in the Tridin and the calcium trial in order 
to determine the effect of calcium alone in this group of patients. 
A large sample size is needed to improve the power of the study in 
order to further examine the effect of fluoride supplementation on bone 
mineral density 
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Chapter10 Conclusion 
The following conclusions may be drawn from our study. 
1. Men and postmenopausal women with obstructive airway disease (OAD) but who 
are not on inhaled steroids have lower fat mass and percentage of body fat content 
compared with the age and BMI matched controls. 
2. Men with OAD but who are not on inhaled steroids have statistically significant 
lower !ean mass compared with the age and BMI matched controls. 
3. Men or post-menopausal women with OAD on inhaled steroids have similar lean 
mass, body fat mass compared with OAD subjects who are not on inhaled steroids. 
4. The BMDs of the total body, lumbar spine(L1-L4), femoral neck, intertrochanteric 
region and Ward's triangle of women OAD patients who are not on inh3led steroids 
are lower than age, and BMI matched controls. However, their differences are not 
statistically significant. 
5. The BMDs of the total body, lumbar spine(L1-L4), femoral neck, intertrochanteric 
region and Ward's triangle of men OAD patients who are not on inhaled steroids 
are statistically significant lower than the age and BMI matched controls. 
6. Inhaled steroids increase the body fat mass among premenopausal or 
postmenopausal female OAD patients compared with the age and BMI matched 
controls, but not in the men OAD patients with similar dose and duration of inhaled 
steroids treatment. 
7. Inhaled steroids increase the fat mass among premenopausal and postmenopausal 
OAD female patients with similar magnitude. 
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8. Inhaled steroids do not affect the lean mass in 〇AD patients compared with the 
age and BMI matched controls. 
9. Inhaled steroids do not affect the percentage of body fat content among women 
and men OAD patients compared with age and BMI matched controls. 
10. The BMDs of the total body, femoral neck, intertrochanteric region and Ward's 
triangle of premenopausal female OAD patients on inhaled steroids are similar, but 
the BMD of the lumbar spine(L1-L4) is statistically significant lower than that of the 
age and BMI matched controls. 
11. The BMD of the lumbar spine(L1-L4) of postmenopausal women OAD patients on 
inhaled steroids are statistically significant lower than that of the age and BMI 
matched controls. 
12. The BMDs of the lumbar spine(L1-L4), femoral neck, intertrochanteric region and 
Ward's triangle of men OAD patients on inhaled steroids are statistical significant 
lower compared with the age and BMI matched controls. 
13. The BMD at the lumbar spine(L1-L4) of men and post-menopausal women OAD 
patients on inhaled steroids are statistical significant lower as compared with the 
age and BMI matched men and post-menopausal women OAD patients not on 
inhaled steroids. 
14. 52% of the Tridin treated patients had certain side effect compared with 34% of the 
calcium treated patients. 
15. Intake of 12 mg fluoride and 371 mg calcium per day for nine months do not 
increase BMD when comparing with the group given 434 mg calcium alone. In fact, 
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both fluoride and calcium groups show decreases in mean BMDs of the lumbar 
spine(L1-L4), femoral neck, intertrochanteric region and Ward's triangle. 
16. The percentage change of BMD is higher in the Tridin treated group. 
17. A similar degree of bone loss between the Tridin and calcium treated groups is 
noted. However, bone loss more rapidly in men OAD patients treated with Tridin. 
18. Site-specific bone loses due to Tridin treatment is found among men and 
premenopausal women OAD patients. Bone losses are more marked at hip 
compared with lumbar spine(L1-L4), but no site-specific bone loss with calcium 
treatment is observed. 
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Appendix 1: Questionnaire for OAD bone mineral 
density study 
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Appendix 1: Questionnaire for OAD bone mineral density study 
1. Name: ( i 
2. Address: 3. Serial Number: ； 
4. Weight: 
5. Height: 
6. HKID Number: 7. Tel no: 
8. Hospital Number 9. Date of birth: 
! D e t a i l e d data on disease, respiratory function and drugs 
(To be extracted from medical records) 








•| Concomitant medical conditions: write down all conditions 
Drug history: 
11. Steroids 
a) Oral: Currentlyonoralsteroids?(1=Y2=N) 11a. 
mg per day for weeks 
mg per day for weeks 
mg per day for weeks 
b) Inhaled: currently on inhaled steroids? (1=Y 2=N) 11b. 
^ig per day for weeks 
^ig per day for weeks 
^ig per day for weeks 
12. Other drugs, written down all current drugs where applicable. 
Cigarette smoking and alcohol consumption 
13. Smoker (1=current; 2=ex; 3=never) 13. 
14. If current or ex smoker, 14(a) cigarette per day for 14(b) years 14a b 
then, 14(c) cigarette per day for 14(d) years 14c d 
then, 14(e) cigarette perday for 14(f) years i4e f 
Smoking 14(q) years; 14(h) cigarette pack year 14g h 
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I 
15. Drinker? (1=current; 2=ex; 3=never) 15 
16. If drinker, for how many 16{i) years and 16(ii) days a week? 16/ /7 
How much a days 
a) Beer(cans) 16a. 
b) Liquor (patts) 16b. 
c) Wine (glass) 16c. 
Physical activity . : 
17 Whatisyourlongestoccupation? 17. 
I 
18. What is your present occupation? 18, 
(l=sedantary; 2=manual; 3=heavy manual) 
19. How would you describe yourself when you were 20 years old ？ 19. 
1) physical active 2) moderately active 3) physically inactive 
20. Can you perform these activities now7(in between attacks) O^es / No) 
a) Walk on the level without feeling dyspnoeic 20.a.— 
b) Walk uphill / upstairs without feeling dyspnoeic 20.b.— 
c) Run without feeling dyspnoeic 20.c. 
21. In the last week, how many days in a week did you perform the following 
a) Walking outdoors 21.a.—days 
b) Walking up a mountain. 21.b.—days 
c) Walking with a load (of 5 Kg or more) 21 .c.一days 
i 22 How many hours did you spends on the following activities last week? 
； a) Tai-chi 22a. hours 
b) Swimming 22b. hours 
, c) Jogging 22c. hours 
d) Ballgames 22d. hours 
e) Dancing 22e. hours 
Calcium intake 
23. Was last week a typical week in your life? If so, can you put down how many times you consume 
the following food-items last week 23. ？ 
No. of average portion size each time times 
a. Milk a. 
b. Milk powder b. 
c. Evaporated milk c. 
d. Soya bean milk d. 
e. Ovaltine or Horlick e. 
f. Ice cream f 
g. Cheese g 
1 3 5 
h. Soya bean curd h. 
i . Soya bean curd cheese I. 
j. Fish j. 
k. Shrimp k. 
I. Crab I. 
m. Dried fish m. 
n. Canned fish n. 
0. Green vegetables o. 
p. Bread p. 
q. Nuts q. 
Average calcium intake mg per day 




3) 2-3 times/week 
4) less: than 1 time/week 
Reproductive history 
25. How old were you when you first had your menstruation ？ 25. 
26. Have you evertaken any oral contraceptives? (yes=1 no=2) 26. 
27. If yes, for how many months? 27. 
28. Do you still have menstruation? (yes=1 no=2) 28. 
29. If not, how many months ago did it stop ？ 29. 
History of fractures 
30. Have you ever had any fracture7(yes=1 no=2) 30. 
31. lfyes,choosefromthefollowing 31. 
1). hip fracture 
2). forearm fracture 
3). vertebral fracture 
32. Has your mother had any fractures? (yes = 1 no=2) 32. 
33. If yes, which of these fractures did she have 33. 
1). hip fracture 
2). forearm fracture 
3). vertebral fracture 
1 3 6 
- . i 
Appendix 2: Bone scans from Hologic QDR 2000 
Figure A2.1 Bone scan image fo「total body composition and bone mineral density 
Figure A2.2 Bone scan f〇「lumbar spine bone mineral density 





1 3 7 
Figure A2.1 Scan image and print out for total body BMD 
Right: Scan image and printout for total body bone mineral data, biography 
and essential quality control data from a OAD pre-menopausal patient. 
Right: Scan image and printout for regional bone mineral data, biography and 
essential quality control data from a OAD pre-menopausal patient. 
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F1B26958A Thu 26.0ct.l99S 10:37 
^ ^ Name： AT-UONG VIM BING, ANNIE 
f . * j Connent： AT 
^ # I.D.： E678274C8) Sex: F 
~ ~ j ¥ m ^ ^ ~ ~ S.S.tt: - 一 Ethnic： K 
‘ ^ & ; ^ ' ^ J ^ ZIPCode: Height： 159.00 cn 
^ 0 ^ ^ W ' 4 ^ * ^ f ^ 此油 e°de: NL Ueight: 62.78 kg 
W / ^ ^ H S ' f \ m BirthDate： 29.Dec.55 Age: 39 
i / ^ ^ A l P h y s i c i a n : 
m ^W^^MM^ \ m Inage not for diagnostic use 
Jk N ^ ^ ^ ^ S ^ ^ TOTAL BMC and BMD CU is < 1.0¾ 
哪 ^ ¾ ^ ^ ¾ 哪 c_F_ 1 腳 1-058 i.eee 
I ffS^% J Region Area BNC BMD 
1 B W WfP| 1 一 (cn2) (grans) (gns/cn2) 
_ M | I ~~L~A^n ""l6i&T89 "^ l izT?! ~~BT616~ 
m 饭 R Arn 164.88 106.16 0.644 
鐘 飄 勵 LRibs 114.61 62.21 0.543 
H l R I 醫 R Ribs 151.61 87.92 6.580 
2 ^ 1 W m TSpine 125.07 113.87 0.910 
后 丨 愁 M L Spine 67.16 67.37 1.8B3 
I ® m , M Pelvis 178.15 198.79 1.871 
^ , ^i^<wr L Leg 327.34 319.B7 8.975 
W i R Leg 334.58 323.96 B. 968 
SubTot 1636.29 1374.87 0.843 
_ _ L _ = _ ^ H e a d 2 5 1 . 3 4 5 6 4 . 4 1 2 . 2 4 6 
•09.Now.1995 10:12 [330 x 152] TOTAL 1881.63 1938.48 1.030 
Hologic QDR-2000 (S/N 2441) ^ ^ ^ ^ ^ ^ 
Enhanced Array Uhole Body M5.67A ^ 
HOLOGIC 
CUHK 
^ ^ ^ F1B26950A Thu 26.0ct.l995 10:37 
[ . ^ J Nane： AT-WONG VIM BING, ANNIE 
% w C o n n e n t： AT 
^ ^ G d M k ^ r I . D. ： E678274 (8) Sex ： F 
> J ^ ^ ^ a ^ J ^ S . S . t t : - - E t h n i c ： K 
M | m ^ l ^ > J ^ ^ ZIPCode： Height： 159.B0 cm 
W T * ^ M i £ f \ m Scan Code： ML Ueight： 62.70 kg 
m / i^jgg^^iMjtl \ p BirthDate ： 29 • Dec • 55 Age ： 39 
f / BiBlS')l Physician： 
H XJ5^:'W"523^^ S Image not for diagnostic use 
m ^ ^ ‘ i ’： ^ ‘ m TBAR552 
^ ¾ ¾ ¾ ^ ' F . S . 68.60y. 6(10.00)y. 
% ^ V v ' M Head assumes 17.0¾ brain fat Uf M' LBN 73.2y. water 
1 l o | V Region Fat Lean+BhC x Fat 
rtB^ ^ M ^ ¾ (Sr rdns> ( g r a n s ) ( ¾ ) 
P ^ 徹 雷 L ^ ^n 1433.4 1529.3 48.4 
1 ^ 1¾ W RArn 1427.8 1541.6 48.1 
k^A gL M 1 Trunk 12424.1 19886.0 38.5 
M l m , ^ L Leg 4330.6 5367.9 44.7 
^ 1 ^ R Leg 4488.9 5326.5 45.7 
.1雕勺 SubTot 24184.9 33651.4 41.7 
Head 867.2 3848.7 18.4 
•09.NL.1995 lB-.i2 [330 J 1523 !OTAL 24972.8 37506.1 40.B 
Hologic QDR-2008 (S/N 2441) ^ ^ ^ ^ ^ ^ 
Enhanced Array Uhole Body U5.67A H O L _ O G C 
Figure A2.1(continue) 
Top: Data summary from body composition analysis and patient biography. 
Bottom: Comparison with the normal range displayed as mean 土 2 SD with 
respect to age- and sex-matched normal subjects (Z - scores) and with 
maximum bone mass of the same population at young adult age (T -
scores). The percentage figures give percent of the mean value of the 
reference population. 
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u , • ™ « � � o o , ,ia o " n Nane： AT-MONG VIM BING, ANNIE Holosric QDR-208e (S/N 2441) 奶 Enhanced Array Whole Body U5.67A ^onnent. "* 
.89.NoM.1995 10：12 I•».: E678274(8) Sex： F 
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R Arm 186.2 1427.8 1435.5 1541.6 2969.5 48.1 
Trunk 522.2 12424.1 19363.9 19886.8 32318.1 38.5 
L Leg 319.1 4330.6 5048.8 5367.9 9698.5 44.7 
R Leg 324.8 4488.9 5882.5 5326.5 9815.4 45.7 
SubTot 1374.1 24104.9 32277.3 33651.4 57756.2 41.7 
"Head 564.4 867.2 3284.3 3848.7 4715.9 18.4 
TOTAL 1938.5 24972.8 35561.6 37580.1 62472.1 40.8 
"assunes 17.0¾ brain fat 
LBN 73.2¾ uater 
^ ^ ^ 
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CUHK 
A Uhole Body^ 
Reference Database • F1B2695BA Thu 26.0ct.1995 18:37 
I I ~~I I I 1 j Nane： AT-UONG VIM BING, ANNIE 
i • 2 卜 i!P#�h I Connent ： AT 
l.lW' 7 ^ T ? ^� ： I.D.: E678274(8) Sex： F 
B i-0H6MSI^**^'^^^®*"®^ - S.S.tt： - - Ethnic： K 
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e!& - _ - BirthDate： 29.Dec.55 ^ge： 39 
® ' S - 一 Physician： B.4 - -
0 . 3 一 — 
B . z L _ I — — i — — I — — I _ J _ J 
26 3e 40 5B 60 70 80 
Age 
BND(UHOLE) = 1.838 g/cP|2 
__TC43B) 2 
+e.62 106:< -0.20 99x 
• l^ gej sex, and ethnicity natched ^ ^ ^ 5 
T Peak bcwie^  nass LJ�I 门厂 P* 




Figure A2.2. Complete bone mineral report for the lumbar spine. 
Top left: Bone mineral image with standard R〇l including L1-L4. 
Top right Biographical and information on bone area, BMC, and BMD. BMD is 
presented for each vertebra and for the entire ROI. Images and data on 
individual vertebrae are used to judge uniformity of bone mineral 
distribution. 
Bottom: Comparison with the normal range displayed as mean 土 2 SD with 
respect to age- and sex-matched normal subjects (Z - scores) and with 
maximum bone mass of the same population at young adult age (T -
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; : ; ' : ^ ^ ^ ^ P ^ ^ ^ ^ Nane： AT-UONG VIM BING, ANNIE 
^ ^ 1 ^ ^ ^ ^ ^ 1 ^ ; ^ ^ ^ ^ ^ ^ ] ¾ ^ ^ I.D. ： E678274(8) Sex： F 
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• ’ : j ^ ; h ^ ^ ^ : ^ ^ J | ^ i a ^ ^ ^ ^ ^ ^ ^ BirthDate： 29.Dec.55 Age： 39 
• ® ^ ^ ^ ^ S f - S : : 、 - d i a _ i c use 
W ^ ^ ^ ^ TOT^ B«D ⑶ FOB L i - L4 i . 0 . 
• ; ^ ^ ^ ^ ^ p p • C . F . 0 . 9 9 2 0 . 9 8 3 1 . 0 0 0 
— — • ^ ^ f ^ l ^ ^ ^ B ^ ^ ^ 、 . ^ 1 Begicm Est.Area Est.BMC BMD 
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^ m l i i i 
• . S _ . ^ ^ I ^ ^ P : : , : - : TOTAL 56.27 56.84 1.018 
•27.0ct.1996 22:39 [113 x 137] .^ 
H o l o g i c QDR-2ee0 ( S / N 2 4 4 1 ) ^ ^ ^ ^ ^ ^ 
Arra|j Spine Medium U4.74A:1 — • CDG C 
p H K 
L^LJI x 
A L u n b a r S p i n e Reference Database • F05189519 Thu 18.May.1995 12:36 
1 r 1 1~~~l 1 1 n Nane： AT-UONG VIM BING, ANNIE 
1 * 2 - I C o n n e n t ' . AT 
^• ^  ^ ^ ^ ^ ¾ ¾ ^ - . I I.D. ： E678274(8) Sex： F 
B 1.0 ^ i S r ^ ^ ^ ^ ' ^ - l S.S.tt： - - Ethnic： K 
n ® • I J J H P H | | j j | | ^ ^ M ^ 7 r ^ Z IPCode ： He ight ： 159.80 cn 
D 0；7 y * _ * * m ^ ^ ^ ^ ^ ^ ^ Scan Code： EL Weight: 61.30 kg 
0!6 - ^ m m H H H I BirthDate： 29.Dec.55 Age： 39 
®-5 “ ^ ^ ^ ^ ^ H H P l i Physician ： 
0.4 - 一 0.3- -
0 . 2 L _ J — — I — — L _ _ I — — I _ J 
20 30 40 50 60 70 88 
Age 
B M D ( L l - L 4 ) = l . e i 0 ff/cn2 
Region BMD T(49T^ Z 
L1 0.967 +1.35 127x +0.71 109y. 
L2 1.023 +1.17 122>s +8.38 104¾ 
L3 1.019 +0.87 llSy. +0.81 l&&y. 
L4 1.827 +0.78 113¾ -8.11 33y. 
Ll-L4 1.010 +1.86 llQy. +0.28 162¾ 
• Agej seXj and e t h n i c i t y matched ^ ^ S 
T=Peak B o n e N a s s LJ「 I 门「 .「 ' 
Z=age natched ML 25 Feb 97 MUL_ULD U 
Figure A2.3. Complete bone mineral「eport of the left proximal femur 
Top left: The ROIs as defined on Hologic instruments are shown: 
1 femur neck ROI 
2 Ward'striangle ROI 
3 Trochanter ROI 
4 lntertrochanter ROI 
5 Centre line of femur neck 
6 Inferior border of trochanter FROI ， 
The entire area covered by neck ROI trochanter R〇l and intertrochanter 
ROI is called the total ROI 
Top right: Biographical and information on bone area, BMC, and BMD are shown. 
BMD is presented fo「femur neck ROI, trochanter ROI, intertrochanter 
ROI. Total ROI. and Ward's triangle ROI. 
Bottom: Comparison with the normal「ange displayed as mean 土 2 SD with 
respect to age- and sex-matched normal subjects (Z - scores) and with 
maximum bone mass of the same population at young adult age (T -
scores). The percentage figures give percent of the mean value of the 
reference population. 
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Appendix 3. Tables and reference curves for normal 
Hong Kong Chinese female or male 
BMD 
1 4 2 
Table A3.1. Total body BMD and lumbar spine(L1-L4) BMD for normal Hong Kong 
Chinese female 
Age Total body Lumbar spine(L1-L4) 
(Year) n Mean SD Mean SD 
15-19 5 1.014 0.0666 0.950 0.0487~~ 
20-24 31 1.012 0.0741 0.943 0.1244 
25-29 35 1.039 0.0605 0.969 0.1063 
30-34 32 1.048 0.0706 0.971 0.1109 
35-39 32 1.039 0.0664 0.966 0.1045 
40-44 43 1.046 0.0666 0.990 0.1001 
45-49 34 1.045 0.0797 0.993 0.1185 
50-54 27 0.999 0.0824 0.899 0.1394 
55-59 32 0.933 0.0980 0.788 0.1447 
60-64 21 0.919 0.0831 0.763 0.0869 
65-69 24 0.863 0.0827 0.712 0.1440 
70-74 38 0.863 0.1415 0.735 0.1859 
75-79 45 0.821 0.0739 0.697 0.0950 
80-84 24 0.834 0.0702 0.730 0.1311 
85-89 2 0.770 0.0099 0.610 0.0644 
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Table A3.2. Total body BMD and lumbar spine(L1-L4) BMD for normal Hong Kong 
Chinese female 
Age ~Femora l neck Intertrochanteric Ward's triangle 
r6gioA 
(Year) n Mean SD Mean SD Mean SD 
15-19 5 0.777~~~0.1017 1.066 0.1272 0.763 0.1220 
20-24 32 0.768 0.0992 0.988 0.1075 0.746 0.1548 
25-29 35 0.781 0.1180 1.045 0.1498 0.753 0.1403 
30-34 32 0.763 0.1341 1.024 0.1622 0.716 0.1713 
35-39 32 0.772 0.0823 1.036 0.1344 0.714 0.0976 
40-44 43 0.775 0.0831 1.049 0.1038 0.701 0.1068 
45-49 34 0.754 0.0869 1.016 0.1179 0.659 0.1215 
50-54 27 0.730 0.0950 0.991 0.1069 0.590 0.1089 
55-59 32 0.645 0.0933 0.874 0.1245 0.484 0.0976 
60-64 21 0.631 0.0844 0.832 0.2115 0.472 0.0966 
65-69 24 0.564 0.0802 0.801 0.1043 0.387 0.0882 
70-74 38 0.569 0.0859 0.786 0.1488 0.382 0.1100 
75-79 45 0.515 0.0699 0.710 0.1125 0.328 0.0813 
80-84 24 0.514 0.0748 0.700 0.1248 0.317 0.0665 
85-89 2 0.428 0.0842 0.553 0.0707 0.230 0.0495 
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Table A3.3. Total body BMD and lumbar spine(L1-L4) BMD for normal Hong Kong 
Chinese male 
Age Totalbody Lumbarspine(L1-L4) 
(Year) n Mean SD Mean SD 
45-49 ?9 1.036 0.0795 0.915 0.1166 
50-54 16 1.006 0.0604 0.859 0.1095 
55-59 14 1.029 0.0633 0.906 0.0875 
60-64 15 1.044 0.0968 0.884 0.1604 
65-69 6 1.044 0.1447 0.998 0.1581 
70-74 46 0.975 0.1612 0.879 0.1521 
75-79 44 0.996 0.1261 0.941 0.1599 
80-84 3 1.012 0.0367 1.035 0.1455 
a M ^ ^ ^ ^ ^ ^ M M M M ^ M ^ ^ ^ ^ M ^ M M M M H ^ ^ ^ ^ ^ H ^ ^ ^ M M M M M a ^ ^ H ^ H ^ ^ ^ H H O T H H M n B B M M H M ^ M ^ M M ^ ^ ^ ^ ^ H ^ ^ ^ ^ H m ^ M M V H M M M M M M H M M M M M H ^ H H H I ^ H ^ H M H M H H M M M M M M M M M M M H M M H M W W M M H M M W M H M 
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Table A3.4. Total body BMD and lumbar spine(L1-L4) BMD for normal Hong Kong 
Chinese male 
Age Femoral neck Intertrochanter Ward's triangle 
(Year) n Mean SD Mean SD Mean SD 
45-49~~^9 0.733 0.0942 1.015 0.1131 0.577~~0.1149 
50-54 16 0.684 0.0940 0.917 0.2288 0.499 0.1061 
55-59 14 0.723 0.0836 1.022 0.1106 0.564 0.1030 
60-64 15 0.719 0.1452 0.953 0.1676 0.510 0.1403 
65-69 6 0.692 0.1286 1.074 0.1919 0.513 0.1859 
70-74 46 0.655 0.0996 0.931 0.1259 0.441 0.0953 
75-79 44 0.663 0.0851 0.942 0.1327 0.444 0.0960 
80-84 3 0.696 0.0285 0.993 0.0973 0.524 0.0585 
I 1 4 6 
Ficjure A3 V Normal bone mineral density values (Mean,SD) for 425 Hong Kong Chinese 
‘ ‘ f e m a l e s measured by Hologic QDR 2000 bone densitometry 
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Figure A3.2: Normal bone mineral density values {Mean,SD) for 163 Hong Kong Chinese 
males age over 45 measured by Hologic QDR 2000 bone densitometry 
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